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Abstract 
 
Tumor Associated Macrophages (TAMs) are involved in cancer proliferation, thus strategies to 
deplete them represent promising tools for chemotherapy. Pharmacological agents with multiple 
activities such as curcumin and RNA interference have been proposed; however their 
employment in therapeutics has been limited because of low systemic bioavailability. Accordingly, 
this thesis described as an innovative therapeutic approach for cancer treatment the 
development of polymeric nanoparticles (NPs) able to (i) increase pharmacokinetics properties of 
biomacromolecules and poor water soluble drugs, and (ii) guarantee TAMs specific targeting.  
The safe and versatile polymer Poly(Lactic-co-Glycolic)Acid (PLGA) has been used for the synthesis 
of NPs by both single (OW) and double (WOW) emulsion-solvent evaporation techniques. 
Different synthetic parameters have been taken into consideration, with particular focus on the 
surfactant role. As alternative to the commonly used Poly Vinyl Alcohol (PVA), a newly synthetized 
polymer (amino-PVA) and Calcium Sterate (CSt) have been investigated for their ability to 
modulate surface charge and biocompatibility. NPs with solid or core-shell structures, whose size 
was tailored between 200 and 300 nm, were obtained and a thorough characterization has been 
performed, with the help of innovative techniques such as single particle optical extinction and 
scattering (SPES) method. Both amino-PVA and CSt stabilized NPs were found to be able to load 
curcumin and biomacromolecules, either alone or in combination. Strategies for surface 
decoration with the employment of D-mannose as specific molecule to guarantee TAMs 
recognition were proposed. Finally, cytocompatibility of the amino-PVA and CSt stabilized NPs 
have been assessed.  
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Introduction 
 
1. The clinical need: Tumor Associated Macrophages and cancer treatment 
 
1.1 TAMs role in tumor development 
 
Macrophages are resident phagocytes originating from blood monocytes. They are widely 
distributed in tissues, where they are active both as immune effectors cells with a broad microbial 
recognition capacity, and as housekeeping phagocytes responsible for maintenance of tissue 
integrity1. In terms of both phenotype and gene expression programs, macrophages display a 
striking heterogeneity that reflects on the one hand the specialization of tissue macrophages in 
the microenvironment of tissues as different as liver, brain, spleen and many others; and on the 
other the dynamic changes in their physiology that occur after they come in contact with 
microbial stimuli or endogenous stress signals (i.e. necrotic cells). Therefore the generic definition 
of macrophages comprises a variety of cells with different functions and functional states that are 
specified by the complex interplay between micro-environmental signals and a general, robust 
differentiation program that determines macrophage identity1. In fact, macrophages are polarized 
following activation into classic inflammatory (M1) or alternatively activated (M2) programs. M1 
cells are activated in response to microbial products and tumor necrosis factor (TNFα), and are 
characterized by a strong propensity to present antigen (Ag). In a polarized response,M1 cells are 
thought to kill intracellular micro-organisms and produce abundant pro-inflammatory cytokines 
TNFα, interleukin (IL-12, IL-23), and pro-inflammatory mediators. On the other hand, alternatively 
activated M2 cells are promoted by various signals such as IL-4, IL-13, glucocorticoids, IL-10, 
immune complexes (IC) which drive autoimmune diseases and some pathogen associated 
molecular patterns. Their mainly characteristics include phagocytic activity, production of 
ornithine and polyamines, high expression of scavenging molecules, as well as the expression of 
mannose and galactose receptors on their surface. Their functions are to resolve inflammation 
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and promote angiogenesis and tissue remodeling (Fig. 1). Differences between M1 and M2 
macrophages also include their chemokine expression profiles2–6. 
 
 
Fig. 1. Monocyte differentiation towards M1 and M2 phenotype. The scheme underlines factors 
involved in monocyte differentiation, as well as M1 and M2 physiological role. 
 
In the context of solid tumors, bidirectional communication between cells and their 
microenvironment as well as the coordinated intercellular interactions are disrupted and 
modified. By the release of cytokines, chemokines and other molecules, tumor can educate cells 
to acquire pro-tumorigenic functions, and in turn the microenvironment evolves to accommodate 
the tumor growing7,8. 
When cancer development is related with inflammation, recruitment to tumor tissues of cells of 
the monocyte-macrophage lineage occurs3,9,10. This influence also the premetastatic niche and 
promote secondary localization of cancer2. The different growth factors and chemokines secreted 
by cancer cells determine a change in macrophage phenotypes1. In this pathological context, 
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Mantovani et al.11 have originally proposed the role of infiltrating leukocytes in facilitating tumor 
growth and progression. Nowadays it is well assessed that tumor cell products, including 
extracellular matrix components, IL-10, CSF-1, and chemokines (CCL2, CCL18, CCL17, and CXCL4), 
switch macrophages phenotype into a M2-like, thus promoting Tumor Associated Macrophages 
(TAMs) formation. TAMs are characterized by low IL-12 and high IL-10 expression. They exert a 
cancer-promoting behavior by presenting low tumoricidal activity and contemporary promotion 
of tissue remodeling and angiogenesis2,9 (Fig.2). In addition, TAM infiltration has been associated 
with poor prognosis, as shown in Hodgkin disease, glioma, cholangiocarcinoma, and breast 
carcinoma2,12,13. 
 
 
Fig.2. Tumor Associated Macrophages role in tumor development (adapted from7). In a tumor 
environment, inflammation can promote Tumor Associated Macrophages (TAMs) formation, thus 
inducing tumor proliferation, angiogenesis, metastasis formation and immune suppression (Ag, 
antigen; NK, natural killer). 
 
1.2 TAMs are a promising target for cancer treatment 
 
Since TAMs are so deeply involved in the pathology of cancer proliferation, strategies to deplete 
them or to inhibit their recruitment into neoplastic lesions have been investigated and some 
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successes in experimental settings have been obtained2,12,14–18. Indeed, when their density in 
tumor tissues was reduced, a marked decrease in the presence of pro-tumor growth and 
angiogenic factors (such as TGF-β, TNF-α, MMP-9, and VEGF) was observed. This consequently 
inhibited tumor angiogenesis, growth and metastasis18.  
In addition, macrophages represent a good target because their stable genome is not likely to 
develop drug resistance19. 
So far, no specific drugs are available for TAMs targeting, with the except of trabectedin that is 
authorized only in the secondary treatment of soft tissue sarcoma and relapsed platinum-
sensitive ovarian cancer17,20–22. Moreover, cost of trabectedin as primary therapy was found to be 
higher than the combination doxorubicin/ifosfamide, thus supporting the recommendation that 
trabected in should remain a second-line treatment23. 
 
 
 
1.3 Possible alternative strategies for TAMs targeting 
 
1.3.1 Curcumin 
 
Curcumin (diferuloylmethane) is a polyphenol (Fig.3) and constitutes the mainactive principle of 
the perennial herb Curcuma longa (also called turmeric)24. 
 
 
Fig.3. Chemical structure of curcumin. 
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Accumulating evidence suggests that curcumin possesses several pharmacological properties with 
a wide range of molecular target. It has been investigated as anti-inflammatory, antimicrobial, 
antiviral, antifungal and antioxidant. Moreover, its properties of chemo and radio-sensitizing as 
well as its wound healing activities have been reported25. The variety of curcumin molecular 
targets comprehends more than 100 molecules, including transcription and growth factors within 
their receptors, cytokines, enzymes, and genes related tocell proliferation and apoptosis24. In 
addition, curcumin acts as antiproliferative agent, since it interrupts the cell cycle by disrupting 
mitotic spindle structures and inducing apoptosis and micronucleation25,26. So far, curcumin has 
been deeply investigated as pharmacological agent with multiple activity24,25,27. 
 
 
Curcumin has anti-inflammatory activity 
Being turmeric present in the traditional Indian Ayurveda24, it has been known from long time 
that this plants exhibits anti-inflammatory activity. However, it was just in the past three decades 
that an extensive research has been performed on the turmeric anti-inflammatory mechanism. It 
was found that curcumin is the actual responsible for turmeric effects27. 
As summarized by Aggarwal and Harikumar27, curcumin was found to exhibit therapeutic 
potential in various chronic disease in which inflammation plays a major role, such as Alzheimer's 
and Parkinson's disease, multiple sclerosis, epilepsy, cerebral injury, cardiovascular diseases, 
allergy, asthma, bronchitis, colitis, rheumatoid arthritis, renal ischemia, psoriasis, diabetes, 
obesity, depression, fatigue, and lastly cancer. 
Anti-inflammatory mechanism of curcumin was firstly demonstrated by Singh and Aggarwal28. 
They found that curcumin acts as a potent blocker of the ubiquitous transcription factor NF-κB, 
whose activation is induced by different inflammatory stimuli. Later on, a large body of literature 
revealed that curcumin could suppress inflammation through multiple pathways27 (Table1). 
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Pathway inhibited by curcumin action 
TNF-α IL-1β IL-6 STAT3 MIP-1α 
HAT COX2 5-LOX ICAM-1 ELAM-1 
VCAM-1 GHS-PO NQO-1 BACE-1 iNOS 
LOX LPO CTGF UPA MMP-9 
CRP VEGF PI3K-AKT ODC NRF2 
HIF-1α NF-κB CXCR4 IFN-γ IL-8 
Table1. Different mechanisms through which curcumin acts as anti-inflammatory drug27 
 
 
Curcumin exhibits antitumor activity 
Until now, the anticancer potential of curcumin has been reported in more than 800 articles27. 
Curcumin anti-proliferative effects have been demonstrated in extensive in vitro studies, as well 
as in different animal models24. In particular, curcumin is able to target several steps of the 
biomolecular pathways involved in carcinogenesis by blocking the transformation, proliferation, 
and invasion of tumor cells29. Accordingly, curcumin is nowadays object of various clinical trials for 
cancer therapy, as reported by Goel et al24. 
 
Curcumin interacts with cells of the immune system altered during cancer development 
Among the variety of curcumin activities against cancer progression, its ability to suppress 
myeloid-derived suppressor cells (MDSC)30 and active macrophages31 is of particular importance. 
Different studies25 have also shown the ability of curcumin to modulate macrophages activation.  
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Curcumin is extremely safe and well tolerated 
In addition to the massive study about curcumin pharmacological effects, a number of clinical 
trials have addressed pharmacokinetics and toxicological profile of curcumin in humans.  
First evidence for curcumin safety is related to the fact that turmeric has been present in human 
diet for long time, as part of the common used spice curry, in a concentration that ranges up to 
100 mg/day24. Orally assumed curcumin can be considered as pharmacologically safe. Moreover, 
recent phase I clinical trials as well as additional reports indicate that a dose of curcumin as high 
as 12 g/day is well tolerated without toxic side effects24,32. 
 
Considering all of these conditions, curcumin presents a great potential for employment in TAMs 
depletion. 
 
1.3.2 “The silencing revolution”: siRNA 
 
Since the Nobel-prize winning discovery of RNA interference (RNAi)33, small interfering RNA 
(siRNA) is considered a potential revolution in therapy, being theoretically able to deregulate the 
expression of all the genes involved in pathogenesis of different disorders, including cancers and 
autoinflammatory diseases34. 
RNAi is a natural phenomenon of gene silencing mediated by RNA and it is highly conserved 
among multicellular organisms. Basically, RNAi is able to inhibit the conversion of messenger RNA 
(mRNA) into proteins. In physiological process, the double-stranded RNA (dsRNA) presents a 
sense (passenger) and an antisense (guide) strand, the latter one complementary to the target 
mRNA. Firstly, dsRNA molecule is recognized by an RNase type III enzyme (Dicer), and cleaved into 
small fragments35–37. These fragments bind to the RNA-induced silencing complex (RISC), located 
in the cells cytosol. The dsRNA passenger strand is then cleaved while the guide strand is directed 
to the 3′ untranslated region of the complementary target mRNA35,38.  
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When dsRNA is not endogenous but exogenously introduced, it takes name of siRNA. After siRNA 
interaction with RISC,the cleavage enzyme “argonaute 2” within the RISC complex degrades the 
target mRNA, thereby preventing protein transcription35. 
So far, therapeutic strategies based on siRNA have been taken into consideration as an alternative 
approach to the pharmacological one in TAMs targeting. A valuable alternative to TAMs depletion 
is the use of siRNA to silence gene expression and normalize TAMs abnormal phenotype. In that 
way, TAMs protumorigenic effects can be countered and replaced by a stimulated anti-tumor 
immunity1,19. 
 
1.3.3 Multiple drug release 
 
Especially in cancer treatment, it is fundamental to consider problems related to drugs toxicology. 
To achieve therapeutic levels, anticancer drugs need to be administered in high dose, and risk for 
developing drugs resistance is prominent. In fact, being tumors originated from a concomitance of 
different mechanisms, one single drug is commonly not sufficient to completely destroy cancer 
cells39,40. A combination of therapeutics is often the preferred treatment.  
Compared to administering each single drug individually, the possibility to encapsulate more than 
one therapeutic molecule in the same delivery system represents a great advantage41. First of all, 
each drug can be specifically targeted at the active site in a correct ratio. Moreover, synergistic 
therapeutic effects, suppression of drug resistance and the ability to temporally control drug 
exposure can be exploited. This includes the opportunity to regulate proliferation, invasion, and 
metastatic process of cancer cells at the same time thanks to the synergetic and complementary 
effects of the selected drug molecules40. 
 
1.3.4 Curcumin and siRNA need to be vehiculated 
 
Despite of its efficacy and safety42, curcumin has not been approved as a therapeutic agent yet. 
The main reason is related to its low systemic bioavailability, since curcumin is poorly adsorbed 
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and rapidly metabolized. Many studies in rats and humans indicated that curcumin reached 
extremely low serum levels and effective concentration was obtained only in the gastrointestinal 
tract43. In this context, NPs represent a suitable tool for encapsulating highly hydrophobic agents 
like curcumin and circumventing major pitfalls of poor aqueous soluble drugs. Indeed, NPs can 
increment curcumin solubility, modulate its route of administration, and improve drug 
bioavailability.  
Similarly, siRNA use in clinics is still challenging due to its in vivo behavior. First, siRNA molecules 
undergo a rapid degradation within the host organisms, due to serum nucleases, renal excretion 
and passive entrapment in organs such as liver and kidneys. In addition, siRNA molecules are not 
able to specifically recognize and target cells or tissues involved in the pathology development. 
Finally, their hydrophilic characteristics do not allow siRNA molecules to cross the cell membrane 
and reach the cell cytosol, where the RISC is located1. To overcome these limits, biodegradable 
polymeric nanoparticles represent a promising tool for improvement in siRNA stability and 
specific delivery at the target site44. So far, very few nanosystems have been developed to 
increase siRNA stability, and the most majority of them relate to lipid nanoparticles or 
bioconjugates44,45.  
 
2. Nanomaterials as a promising tool for drug and gene delivery 
 
2.1 Nanomaterials 
 
Improvement in pharmacokinetics properties of the drugs is one of the major issues in drug 
formulations and pharmaceutical technology46. This is of particular importance when proteins and 
genes are used as therapeutics. In fact, their application in clinics seems hard to be reached 
because of the arduous in vivo fate of these biomacromolecules. First, after administration of 
proteins and genes, a rapid degradation occurs within the host organisms, due to serum 
nucleases, renal excretion and passive entrapment in organs such as liver and kidneys. Moreover, 
since cell membrane is highly selective and has poor permeability to hydrophilic molecules a 
number of physical barriers prevent biomacromolecules from reaching the cell cytosol, where 
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they are supposed to exert their effects. Finally, when endocytosis occurs, it is possible that 
biomacromolecules degradation takes place in the lysosome47–49.  
To overcome these limits, encapsulation of biomacromolecules and poorly water soluble drugs in 
nanomaterials (NMs) represents a promising tool.  
Definition of NMs include systems with at least one of the three spatial dimensions below 1 µm 
and the term nanotechnology refers to the intentional synthesis, manipulation and use of objects 
with size in the nano range50,51. Fig. 4 summarized the great variety of NMs that can be 
synthesized to obtain structures with novel physical or chemical properties. 
 
 
Fig. 4. Overview of available nanomaterials. In the scheme, nanomaterials are classified in base 
of their chemical nature. 
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The characteristics of NMs from the physical-chemical point of view may radically differ from 
those of the corresponding bulk materials52. Indeed, the latter usually present features that are 
independent on their shape and size. Differently, NMs properties are strictly related to the high 
increase in surface-to-volume ratio, as well as the fraction of atoms on the surface with respect to 
the total number of atoms in the material52. In this way, different characteristics such as materials 
coordination number, cohesive energy, melting point and temperatures of phase transitions are 
modulated. In the case of NMs, all of these characteristics have been found to be size and shape-
dependent50,52.  
By properly engineering NMs synthesis, it is possible to design systems for drugs and genes 
administration. So far, NMs have been functionalized to avoid renal excretion53,54, improve 
molecules bioavailability as well as their stability55, and specifically target tumor vasculature56,57, 
other specific tissues58–60 or even cellular compartments48,61,62. In fact, larger surface-to-volume 
ratio improves the opportunity for surface functionalization of NMs, which is fundamental for 
technological application, especially in drugs or genes delivery50. 
Moreover, with respect to micron-size particles, NMs present increased capability to extravasate 
from the endothelium. This is of particular importance to target pathological sites such as 
inflamed tissues and tumors via the enhanced permeability and retention (EPR) effect. NMs can 
also penetrate microcapillaries and epithelium in the intestinal tract and in the liver63,64. Being 
smaller than the smallest capillaries in the body (5-6 µm), NMs are extremely suitable for systemic 
administration because they can be distributed in the bloodstream without forming aggregates, 
thusavoiding embolism63. 
Finally, the nanometric size improves NMs uptake by different cell types, thus helping drug 
accumulation at target sites63,65–67.  
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2.2Polymeric nanoparticles 
 
Among the great variety of NMs, this thesis especially explores the potential of polymeric 
nanoparticles (NPs) as a tool for gene and drug delivery. In fact, the NMs presented here combine 
the advantages of nano-sized objects with biodegradability and biocompatibility of polymeric 
materials51,68–70.  
NPs are solid, colloidal particles consisting of macromolecular substances that vary in size from 10 
nm to 1000 nm71–73. Their matrix interacts with drug and macromolecules of different nature by 
dissolution, entrapment, adsorption, attachment and/or encapsulation63. 
NPs properties can be controlled and adjusted during their synthesis, thus conferring versatility to 
the system. In fact, the design of nano-sized polymer-based particles has attracted more and 
more attention due to their wide applicability in modern material and medical science74,75. In 
therapeutic applications, the use of drug or gene-loaded NPs has improved drug efficacy, 
specificity, tolerability and therapeutic index of corresponding drugs76,77. In fact, NPs systems 
considerably increase the drug payload, being each single NPs able to carry thousands therapeutic 
molecules41. Moreover, NPs avoid drug degradation while increasing its bioavailability, retention 
time and intracellular penetration. Appropriate NPs surface functionalization allows specific 
targeting and NPs chemical properties enhance their interaction with biomolecules, such as 
genetic materials, proteins or drugs. Fig. 5 schematically represents various opportunities to 
modulate polymeric NPs properties thus underlining the great versatility of these systems. 
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Fig. 5. Overview of polymeric nanoparticles and their functionalization. (PEG, polyethylene 
glycol) 
 
Polymeric NPs can present different structures depending on their synthetic method (see 
paragraph 2.2.2.2 Synthetic methods for PLGA NPs page 34 in the introduction section). 
Surface functionalization can be additionally obtained by proper chemical modification, thus 
improving NPs stability as well as their capabilities for specific targeting. These features are also 
influenced by particle size, surface charge, and hydrophobicity. In particular, both the size and size 
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distribution of NPs are important to determine their interaction with the cell membrane and to 
control the penetration across the physiological barriers78,79. 
 
2.2.2. Poly(Lactic-co-Glycolic) Acid Nanoparticles 
 
2.2.2.1 Poly (Lactic-co-Glycolic) Acid (PLGA) 
 
In order to avoid most of the problems associated with natural polymers, in terms of cost, 
production, safety and allergic reaction, synthetic polymers have been increasingly used for the 
design of polymeric NPs80. For this purpose, different polymeric classes have been explored, such 
as poly(amides)81, poly(amino acids)82,83, poly(alkyl-α-cyano acrylates)84,85, poly(esters)86,87, 
poly(orthoesters)88, poly(urethanes)89,90, and poly(acrylamides)91,92. Amongst them, great success 
has been obtained by thermoplastic aliphatic poly(esters) like Poly Lactic Acid, Poly Glycolic Acid, 
and particularly poly(lactic-co-glycolic) acid (PLGA) (Fig.6), because of their biocompatibility and 
biodegradability87. 
 
 
Fig.6. Chemical structure of Poly (Lactic-co-Glycolic) Acid (PLGA). 
 
In this dissertation, main focus was on developing PLGA-based NPs. Indeed, PLGA products for 
drug delivery and diagnostics have been already approved by Food and Drug Administration (FDA) 
and are available in the market67,87,93,94. PLGA is associated with reduced in vivo toxicity thanks to 
its biodegradability properties. In fact, the degradation mechanism through hydrolysis leads to 
the release of lactic acid and glycolic acid. These monomers are endogenous and can be easily 
metabolized because they enterin a number of physiological and biochemical pathways68,94,95. 
Additionally, PLGA is commercially available with different molecular weights and monomeric 
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ratio, thus allowing the possibility to tune polymer degradation time94,96. In fact, lactic acid is more 
hydrophobic than glycolic acid. Accordingly, PLGA copolymers containing higher amount of lactide 
monomer are consequently less hydrophilic, absorb less water, and degrade slower87,93. 
 
2.2.2.2 Synthetic methods for PLGA NPs 
 
Several methods are available for PLGA NPs synthesis and they resultin different NPs 
structures63,94,97. In particular, as can be seen in the scheme (Fig.7), a nanocapsular structure is 
present when the drug or biomacromolecule is encapsulated in the inner NPs core. In this way 
NPs present a core-shell structure. Differently, when the selected drug or molecules is either 
entrapped or adsorbed in the polymeric matrix, the NPs structure obtained is a nanosphere. In 
this case, NPs matrix is compact and homogeneous.  
 
 
Fig.7. Graphical scheme of nanosphere and nanocapsule. 
 
One of the most common techniques for PLGA NPs synthesis is the emulsion-solvent evaporation 
method87,93,94. This synthesis allows the encapsulation of hydrophobic and/or hydrophilic 
molecules in mild conditions, thanks to the use of small volume of organic solvents, and no 
elevated temperature or high vacuum. In general, polymer is dissolved in an organic solvent and 
the oil-in-water (OW) emulsion is obtained by adding a surfactant solution. Sonication or 
homogenization is used to induce the formation of nano-sized droplets. The solvent is then 
evaporated or extracted and the NPs collected after centrifugation. NPs obtained in this way are 
nanospheres, with a homogeneous matrix structure. To encapsulate hydrophilic molecules (such 
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as hydrophilic drugs, peptide, antibodies, nucleic acids) and obtain a core-shell structure, a double 
water-in-oil-in-water (WOW) emulsion is necessary. The aqueous inner solution is firstly 
emulsified with the organic polymeric solution and the obtained water-in-oil emulsion is further 
emulsified with the surfactant phase.  
Another commonly used technique for PLGA NPs synthesis is based on nanoprecipitation93,94. In 
this case, PLGA and the drug are both dissolved in an organic solvent, and the solution is then 
added drop by drop to a high volume of aqueous solution. After solvent evaporation, NPs can be 
collected. This system is successful for nanospheres formation, with encapsulation of hydrophobic 
molecules, while biomacromolecules can be loaded only by adsorption on NPs surface after 
production94,95. In this way entrapment efficiency is low and hydrophilic molecules are susceptible 
to denaturation, aggregation, oxidation and cleavage, particularly at the NPs surface-aqueous 
phase interface. Moreover, nanoprecipitation synthesis is an expensive method because of the 
higher amount of organic solvent employed95.  
Other available techniques includes the spray-drying method, salting-out, dialysis and 
supercritical fluids technologies73,94,97. The application of these techniques is limited by various 
inconvenient, such as working with costly dedicated apparatus, low yield on encapsulation, high 
energy consumption or difficulties in purification of non-biocompatible reagents98. Accurate 
description of these techniques is beyond the aims of this thesis and further details can be found 
in the literature73,94,97. 
 
3. Challenges in drug and gene delivery with PLGA NPs 
 
3.1 PLGA NPs interface with complex medium 
 
One of the major challenges for NPs use in drug and gene delivery is related to their interaction 
with cells, lipid bilayers, biological membrane and biological medium in general99.  
Once in the bloodstream, NPs can encounter different fates. First of all, they can be recognized by 
the host immune system and rapidly cleared from the circulation by phagocytes63. Moreover, NPs 
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with a very active surface can be rapidly opsonized and consequently removed by the 
mononuclear phagocyte system (MPS) present in different organs such as liver, spleen, lungs and 
bone marrow63. Degree of opsonization and NPs lifetime in the blood are strictly dependent on 
the NPs interaction with macromolecules, especially proteins, in the bloodstream. In fact, it is 
nowadays well known that macromolecules spontaneously accumulate at the NPs-water 
interface, thus creating a sort of additional coating that alter the NPs adsorption properties99,100. 
This “protein corona” is composed by soft and hard components. While the first is dynamically 
and rapidly exchanged from the particles to the medium, the latter presents a high affinity for the 
NPs surface and is not removable by simple centrifugation100.  
This protein corona greatly influence NPs biological response, including cellular uptake, clearance 
route and accumulation in target organs100–102. In fact, NPs internalization is generally mediated by 
an active process, because NPs size does not allow passive passage through physiological 
membrane. In such an active internalization, the primary contact between NPs and cells mediated 
by NPs surface is fundamental. Thus, alteration in the surface means alteration in NPs-biological 
interaction101.  
The protein corona formation is influenced by chemical property of the nanomaterial, as well as 
its size and surface features. In particular, the latter two characteristics are proved to be more 
important than NPs material on influencing the composition of the hard corona, and consequently 
the NPs biological interactions100.  
During NPs synthesis, maintaining a rigid control on the NPs surface properties is fundamental to 
foresee their fate when in contact with biological medium99. The most reliable parameter for 
assessing NPs surface properties as well as their stability is represented by the ζ-potential63. In 
fact, ζ-potential values lower than -20.0 mV or higher than +20.0 mV usually ensure electrostatic 
repulsion between NPs and prevent NPs aggregation63,103–105 (see also paragraph 5.1 “Dynamic 
light scattering” page 54 in the materials and methods section). 
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3.2Endosomal escape 
 
For both curcumin and siRNA treatment, it is essential to deliver NPs content in the cells cytosol, 
where the drugs can exert their effect. As presented in paragraph 3.1, due to their size NPs cannot 
enter the cells via passive transport through physiological membrane and an active process is 
required.  
One of the possible way through which macromolecules and particles can be internalized from 
the extracellular environment is endocytosis, either mediated or not by receptors. In this process, 
the plasma membrane invaginates and internalizes externally disposed solutes, macromolecules, 
and pathogens106. The so formed vesicle represents the early endosome and becomes 
progressively acidic, thus maturing into the late endosome. In fact, the proton pump vacuolar 
ATPase accumulates protons in the vesicle until a pH around 5-6 is reached. Process generally 
ends when the late endosome fuses with the lysosome, where the content is degraded by 
enzymes and highly acidic pH (4-5)48,107. Considering this mechanism, after internalization NPs 
have to escape from the endosomal pathway to avoid degradation and more importantly 
torelease their cargo into the cytoplasm (Fig. 8).  
 
 
Fig. 8. Graphical scheme of endosomal escape for cytosol targeting. In the scheme, RISC complex 
localization in the cell cytosol was underline for therapy based on siRNA. 
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4. Proposed strategies for drug and gene delivery 
 
4.1 Modulate NPs surface charge: amino-PVA as surfactant 
 
PLGA NPs are frequently obtained by emulsion-solvent evaporation method to encapsulate 
hydrophilic biomacromolecules (paragraph 2.2.2.2 Synthetic methods for PLGA NPs page 34 in the 
introduction section),which could be irreparably denatured in their tertiary structure when harsh 
conditions are applied94,108,109. In this type of synthesis, an emulsifier is required and polyvinyl 
alcohol (PVA) is commonly the preferred one because it forms uniformly dispersed NPs of 
relatively small size and allows good drug entrapment efficiency97,108,110–112.  
Due to its polymeric nature, PVA forms an interconnected network with PLGA at the interface, 
and even after purification its residual constitute up to 13% of the NPs weight113,114. Such a high 
percentage of surfactant localized on the NPs surface could influence their interactions with the 
biological environment115,116.  
In this context, chemical modification of the PVA structure additionally improve the NPs ability to 
enter the cells and especially to escape the endosomes97,117. In particular, the presence of positive 
charges on the surfactant chemical structure, and consequently on the NPs surface, helps the 
binding with negatively charged group on the cells surface. In that way a great efficiency in cell-
membrane penetration and cellular internalization can be achieved99. Moreover, cationic NPs 
produce an osmotic imbalance that destabilized the endosomal membrane. In this way, the 
organelles membranes become leaky and allow the encapsulated molecules to exit and reach the 
cell cytosol62.  
To date, positively charged PLGA NPs have been synthesized by either nanoprecipitation118,119 or 
self-assembly120,121. However, both these methods present some drawbacks. In fact, in the 
nanoprecipitation synthesis, hydrophilic biomacromolecules may be denatured by organic solvent 
exposure, whereas the self-assembly involves multi-step and time-consuming procedures. So far, 
only few efforts have been done to achieve positively charged PLGA NPs by emulsion-based 
methods105.  
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In this thesis, a PVA-based surfactant containing tertiary amines (amino-PVA) was synthesized and 
characterized from the chemical point of view. The surfactant properties of the developed amino-
PVA were investigated either alone or in combination with PVA, in different kinds of emulsion 
syntheses.  
 
4.2 Modulate NPs compatibility: calcium stearate as surfactant 
 
PVA has been the favorite emulsifier in the synthesis of PLGA NPs because of its ability to form 
stable and uniformly distributed NPs. However, disadvantages in the use of PVA may be related to 
a partial evidence of toxicity, especially when the surfactant is used at high molecular weight122. 
Moreover, PLGA NPs with high amount of residual PVA were found to present relatively low 
cellular uptake115. 
Another important aspect from an economic and ecological point of view that is strongly 
underestimated during NPs engineering and manufacturing processes is the waste of raw 
materials and their consequent disposal cost. Some authors112 considered that in emulsion-
evaporation synthesis the external water phase is commonly added in great excesswith respect to 
NPs concentration. In this way a huge amount of surfactant is used, meaning that it has to be 
bought and removed after NPs synthesis. This results in increased productive costs and high 
volume of contaminated water that must be safely disposed of. Moreover, additional energy is 
necessary to collect and purify NPs after synthesis.  
It is therefore imperative to look for an alternative surfactant to be used in formulating 
biocompatible PLGA NPs. This surfactant should guarantee NPs stability, size and polydispersity 
similar to PVA-synthesized NPs, while improving biocompatibility and safety. To date, several 
chemicals have been studied as alternatives to PVA, in particular polymers, such as 
Polyvinylpyrrolidone and poloxamer112, and surfactants like Tween 60®, Tween 80® or 
thePluronic® family108. However, to the best of our knowledge, low molecular weight molecules 
have not been explored so far to synthesize PLGA NPs.  
40 
 
In the present dissertation, the employment of calcium stearate (CSt) (Fig.9) as an alternative to 
PVA was investigated in order to gain cost-effective, stable and safe PLGA NPs. 
 
 
Fig.9. Chemical structure of calcium stearate (CSt). 
 
CSt is a promising surface active agent presenting two linear chains with an 18-carbon length tail 
and a carboxylated hydrophilic head each. Its low MW (607.03 g/mol) is expected to provide a 
lower toxicity with respect to high MW surfactants123. In addition, CSt has very low cost and it has 
already been used for several patented medical devices and scaffolds for tissue engineering. 
However, the influence of CSt on encapsulation efficiency, size and structure of nano- and 
microparticles was not thoroughly studied so far. 
 
4.3 NPs surface decoration 
 
4.3.1 Protein corona as biocompatible additional coating 
 
The prediction of NPs fate in the body in terms of pharmacokinetics and biodistribution is 
challenging, mainly because protein binding and consequent protein corona formation are 
difficult to predict124. Indeed, biomacromolecules adsorbed on NPs surfaces are different from 
those adsorbed on flat surfaces with the same chemical composition101. Even if a number of 
studies have been performed and many techniques (such as differential centrifugal sedimentation 
DCS, Field Flow Fractionaction FFF, proteomics) are available for determining the protein corona 
composition, a huge number of variables make difficult this task.  
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Moreover, it is nowadays accepted that hard corona constitutes the effective unit through which 
NPs interact with cells (see paragraph 3.1 PLGA NPs interface with complex medium page 35 in 
the introduction section). Since proteins can physically cover active targeting moieties on the NPs 
surfaceor interfere with their specific functions, the biological outcomes of NPs can be 
significantly altered with respect to predicted activity. 
The protein corona formation is related to chemical composition, surface features and size of 
NPs125. It should be thereby possible to manipulate the NPs biological coating by controlling these 
parameters, thus providing NPs with desired properties. Alternatively, careful selection of the 
molecular content in the suspending medium may modulate the protein corona composition and 
NPs surfaces can be enriched with molecules of interest. Accordingly, the protein corona 
formation can be transformed froma problem to an opportunity for NPs specific targeting.  
 
4.3.2 D-mannose for specific TAMs targeting 
 
In this work, D-mannose (Fig.10), a hexose monosaccharide isomer of glucose, was selected as 
specific ligand for TAMs targeting.  
 
 
Fig.10. Chemical structure of D-mannose. 
 
It is largely established that mature macrophages highly up regulated on their surface the 
mannose receptor CD206120,126. Consequently,the development of mannose coated PLGA NPs may 
emerge as a prospective strategy for the selective delivery of anti-cancer agents towards TAMs. 
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The mannose receptor family is a subgroup of the C-type lectin superfamily, uniquely presenting a 
multiple C-type lectin-like domains within a single polypeptide backbone. Mannose receptor 
CD206 recognizes proteins bearing terminal mannose residues such as glycosylated lysosomal 
enzymes, saccharide chains terminating in mannose, fucose or N-acetylglucosamine. Initial 
interest in this receptor derived from its ability to recognize and internalize a unique spectrum of 
monosaccharides and lysosomal enzymes bearing terminal mannose residues. Once activated, all 
the mannose receptor family members are rapidly internalized from the plasma membrane via 
clathrin-coated vesicles and enter into the endosomal pathway127. 
Mannosylation has been described as a safe procedure to ensure targeted delivery of anti-cancer 
drug to tumor site, with reduced access to not specific target tissues. In this way it was possible to 
optimized therapeutic response and efficacy, with minimal side effects120,128. 
 
5. Thesis aims 
 
This dissertation is related to the development of polymeric NPs for the specific targeting of 
Tumor Associated Macrophages (TAMs) as an innovative therapeuticapproach for cancer 
treatment. 
TAMs are deeply involved in the pathology of cancer proliferation, thus strategies to deplete them 
or inhibit their recruitment into neoplastic lesions represent promising tools for chemotherapy. So 
far, no specific drugs are available for TAMs targeting, with the exception of trabectedin. 
Accordingly, here innovative treatment based on curcumin or RNA interference has been 
proposed. To date, the employment of these molecules in therapeutics has been limited because 
of their low systemic bioavailability and their rapid degradation.  
To overcome this limits, nanomaterials (NMs) have been presented as a tool for encapsulation of 
biomacromolecules and poorly water soluble drugs. Among them, polymeric NPs have been 
selected because they present the advantages of nano-sized objects combined with 
biodegradability and biocompatibility of polymeric materials.  
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In this thesis, poly (Lactic-co-Glycolic) Acid (PLGA) as safe and versatile materials have been used 
for the development of polymeric NPs by either single (OW) or double (WOW) emulsion-solvent 
evaporation methods. Different synthetic parameters have been thoroughly investigated, with 
particular focus on the surfactant role. 
In order to modulate NPs surface charge and improve their potential for endosomal escape, a 
cationic newly synthesized polymer (amino-PVA) has been proposed.  
Additionally, PLGA NPs biocompatibility and cost-effectiveness have been improved by the 
employment of CSt as innovative surfactant.  
Finally, to ameliorate NPs biocompatibility and specific targeting for both amino-PVA and CSt 
stabilized PLGA NPs, strategies for surface decoration with proteins and D-mannose have been 
investigated. 
 
  
44 
 
Materials and Methods 
 
1. Materials 
 
Poly(Lactide-co-Glycolide)acid (PLGA) with different monomer ratio and molecular weight were 
purchased from Sigma Aldrich, namely (i) 50:50, MW 38-54,000 (Resomer RG504®, ester 
terminated); (ii) 50:50, MW 7-17,000 (Resomer RG502®, ester terminated); (iii) 81:15, MW 190-
300,000 (Resomer RG858®, ester terminated). If not differently stated, Resomer RG504® was 
employed. 
Poly(Vinyl) Alcohol (PVA, Mowiol® 4-88 MW 31,000, 86.7-88.7 mol% hydrolysis), curcumin from 
Curcuma longa (Turmeric), ethyl acetate, calcium stearate 6.6-7.4% Ca basis (CSt), polysorbate 60 
(P60), Span® 60 (sorbitanemonostearate, S60), D-mannitol, vinyl acetate, ethylen glycol, 
acetonitrile (CH3CN), N-(3-(dimethylamino)propyl)methacrylamid (DMAPMA), ammonium 
persulfate (APS), acetone, Fetal Bovine Serum (FBS), ethanol (EtOH), Dimethyl sulfoxide (DMSO), 
fluorescein isothiocyanate (FITC), dichloromethane (DCM), chloroform, D-mannose, sodium 
chloride (NaCl), trehalose, were obtained from Sigma Aldrich and used without further 
purification.  
The PVA with MW 22,000 and 98 mol% hydrolysis was purchased from VWR international.  
Alexa Fluor® 488 goat anti-mouse IgG1 (isoform γ1, IgG1-488) and fibrinogen from human plasma 
Alexa Fluor® 647 conjugate (Fib-647) were obtained from Life Technologies.  
Phosphate Buffer Saline (PBS) was prepared by mixing 136.9 mM sodium chloride, 2.7 mM 
potassium chloride, 3.2 mM sodium phosphate dibasic dehydrate, 1.5 mM potassium phosphate 
monobasic. The pH value was adjusted by means of sodium hydroxide or hydrochloric acid, as 
appropriate. IgG1-488 was diluted in a medium containing 0.1 M sodium phosphate, 0.1 M NaCl 
and 5.0 mM sodium azide. All of these chemical were purchased by Sigma Aldrich. 
Vegetal RNA extract was a kind gift of the Plant Model System Platform (Filarete Foundation, 
Milan, Italy). 
ProLong® Gold was a kind gift of the Imaging Platform (Filarete Foundation, Milan, Italy). 
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Bidistilled water (MilliQ, Millipore) was used in all the experiments. 
For cytotoxicity studies, RAW264.7 (American Type Culture Collection, ATCC) murine 
macrophages were selected as a model cell line. Cells were grown in Dulbecco minimal essential 
medium (DMEM) containing 10.0% fetal bovine serum (FBS) and 2 mM glutamine. In addition, 
primary culture of mouse bone marrow-derived macrophages was investigated. Cells were grown 
in high glucose DMEM supplemented with 20.0% v/v low endotoxin FBS, 30.0% v/v L929-
conditioned medium, 1.0% v/v glutamine, 1.0% v/v Pen/Strep, 0.5% v/v sodium pyruvate, and 
0.1% v/v b-mercaptoethanol. These experiments were performed thanks to the collaboration of 
Dr. Serena Ghisletti at the European Institute of Oncology (Milan), department of Experimental 
Oncology. 
Statistical analyses were performed by means of the Origin software. The free available software 
Image J was used for particle analysis on Scanning Electron Microscopy images. 
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2. Instruments 
 
Centrifuges: Eppendorf 5415R and Heraeus multifuge X3R, Thermo scientific 
Confocal microscope: Leica TCS SP5 AOBS, Leica Microsystems GmbH and Leica TCS SP8 
microscope equipped with a gated-STED module, Leica Microsystems GmbH 
Dynamic Light Scattering: Zetasizer Nano ZS90, Malvern Instruments 
Fourier transformed infrared spectroscope: Cary 660, Agilent 
Freeze dryer: Telstar Cryodos 50 
Nuclear Magnetic Resonance: Bruker Avance 400 
Scanning electron microscope: Zeiss Sigma, Carl Zeiss NTS GmbH 
Spectrofluorometer: FluoroMax 4, Horiba, JobinYvon 
Transmission Electron Microscope: FEI Tecnai 200kV 
Ultrasound probe: Vibracell VCX130, net power output 130 Watts, frequency 20KHz 
UV-Vis spectrophotometer for small volume: Nanodrop® 1000, Thermo Fisher 
UV-Vis Spectrophotometer: Cary 100, Agilent 
UV-Vis Spectrophotometer: TECAN Sunrise (for MTT test) 
X-ray photoelectron spectroscope: UHV apparatus Leybold LH 10/12 
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3. Samples name (Table2) 
Surfactant  Sample name Synthetic procedure Structure 
Encapsulated 
biomolecule 
Polyvinyl 
Alcohol (PVA) 
P0.2-OW-Cur Oil-in Water (OW) Solid Curcumin 
P0.2-OW-ctr OW Solid None 
P1-OW-ctr OW Solid None 
P0.2-IgG-488 
Water-in-Oil-in-Water 
(WOW) 
Core-shell IgG1-488 
P1-IgG-488 WOW Core-shell IgG1-488 
P1-vRNA WOW Core-shell Vegetal RNA 
P0.2-ctr WOW Core-shell None 
P1-ctr WOW Core-shell None 
Amino-PVA 
A-OW-Cur OW Solid Curcumin 
A-OW-ctr OW Solid None 
A-fib WOW Core-shell Fib-647 
A-FITC WOW Core-shell FITC 
A-cur-fib WOW Core-shell 
Fib-647 and 
curcumin 
A-ctr WOW Core-shell None 
Calcium 
stearate 
C-OW-cur OW Solid Curcumin 
C-OW-ctr OW Solid None 
C-fib WOW Core-shell Fib-647 
C-FITC WOW Core-shell FITC 
C-ctr WOW Core-shell None 
C-cur WOW Core-shell Curcumin 
C-cur-fib WOW Core-shell 
Fib-647 and 
curcumin 
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4. PLGA NPs synthesis 
 
The PLGA nanoparticles were synthesized by either single (OW) or double (WOW) emulsion 
solvent evaporation methods78,94. Different surfactants were employed in order to obtain systems 
able to encapsulate hydrophobic or hydrophilic drugs and syntheses were modified accordingly. 
 
4.1 Synthesis of PLGA NPs with PVA 
 
To obtain PLGA NPs by OW method (P0.2-OW-ctr and P1-OW-ctr), PLGA was dissolved in 300 µL 
of ethyl acetate at the concentration of 50.0 mg/mL. The PLGA solution was emulsified with 600 
µL of PVA at different concentrations by ultrasound (30% amplitude, 15 sec, ice bath) and the 
obtained emulsion was diluted with 50 mL of PVA 0.3% w/v. Then, the organic solvent was 
evaporated via magnetic stirring for 3.5 h.  
Differently, the PLGA NPs with an aqueous inner core (P0.2-ctr and P1-ctr) were prepared by a 
two steps procedure. First, an aqueous solution of PBS 0.1X (15 µL) was added to the PLGA/ethyl 
acetate solution (50.0 mg/mL) and sonicated at 30% amplitude for 15 sec in ice bath, to obtain 
the primary water-in-oil emulsion. This emulsion was then added to 600 µL of PVA at different 
concentrations and sonicated using the same protocol described above, to achieve the multiple 
water-in-oil-in-water emulsion. Finally, the WOW emulsion was diluted in the dispersing phase 
(50.0 mL PVA 0.3% w/v) and the organic solvent was evaporated via magnetic stirring for 3.5 h.  
To note, P0.2 and P1 in the PVA stabilized PLGA NPs name referred to the PVA quantity used in 
the syntheses, namely 0.2% and 1.0% w/v. 
 
 
4.1.1 Encapsulation of hydrophobic molecule: curcumin 
 
To obtain samples encapsulating a hydrophobic drug (P0.2-OW-cur), curcumin was dissolved in 
the PLGA-ethyl acetate solution at the concentration of 5.0 mg/mL. In this way, curcumin-PLGA 
ratio was 1 to 10, that is described as the best drug-polymer ratio129–131. 
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4.1.2 Encapsulation of hydrophilic molecules: IgG1-488, vegetal RNA 
 
In the systems obtained by WOW emulsion, two different model macromolecules were 
encapsulated in the aqueous inner core. In particular, IgG1 conjugated with Alexa488® (IgG1-488) 
was selected as a model antibody with fluorescence properties. IgG1-488 was added at the 
concentration of 0.1 mg/mL (P0.2-IgG-488 and P1-IgG-488) and diluted in a solution of 0.1 M 
sodium phosphate, 0.1 M NaCl and 5.0 mM sodium azide, as reported by the manufacturer.  
In addition, RNA was encapsulated (P1-vRNA) to evaluate the system suitability for gene therapy 
application. In particular, a mixture of RNA extracted by Arabidopsis was used and named 
“vegetal RNA”. Final vegetal RNA concentration was 0.15 mg/mL, as assessed by Nanodrop®. 
 
4.2 Synthesis of PLGA nanoparticles with amino-PVA 
 
4.2.1 Synthesis and characterization of amino-PVA 
 
The polymer was synthesized by APS-initiated free radical polymerization.  
Free radicals are unpaired electrons that are highly reactive and have short lifetimes. In free 
radical polymerizations, each polymer chain grows by addition of monomer to the free radical of 
the growing chain. Upon addition of the monomer, the free radical is transferred to the new chain 
end. This kind of reaction typically occurs when unsaturated monomers are present, such as vinyl 
or vinylidene. Reaction takes place after formation of free radical, thanks to the presence of a 
trigger, such as hydrogen donors like amines. Dissociation of an initiator (I) yields two radicals (R•) 
with dissociation rate constant Kd: 
 
𝐼 → 2𝑅 • 
 
This radical then attacks to a monomer molecule to create the first radical M• and in this case Ki is 
the rate constant of initiation. 
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𝑅 • + 𝑀 → 𝑅𝑀 • 
 
The free radicals formed are very active and immediately add on monomer molecules leading to 
growing macroradicals. Each addition creates a new radical that has the same identity as the 
previous one, except that it is larger by one monomer unit. In the polymerization mechanism, it is 
assumed that all growing chains have the same propagation constant (kp). The successive 
additions may be represented by: 
 
𝑀𝑛 •  + 𝑀 →  𝑀𝑛+1 • 
 
Termination usually occurs by combination  
 
𝑀𝑛 •  + 𝑀𝑚 • →  𝑀𝑛+𝑚 
 
or disproportionation reactions. 
 
𝑀𝑛 •  + 𝑀𝑚 • →  𝑀𝑛 +  𝑀𝑚 
 
In detail, 4 mL of vinyl acetate 50.0% v/v in water were added to 4 mL of DMAPMA. The mixture 
was left overnight under magnetic stirring in presence of ammonium persulfate as a trigger. The 
resultant polymer was then collected after precipitation with acetone, and purified by ultra-
filtration using 1000 Da cut-off semi permeable membrane (Millipore). Amino-PVA was obtained 
as fine yellowish powder after freeze-drying (Telstar Cryodos 50 freeze-dryer). 
To assess chemical properties of the obtained polymer after synthesis, Fourier-transform infrared 
spectroscopy (FT-IR, Cary 660, Agilent) and Nuclear Magnetic Resonance (NMR, Bruker Avance 
400, operating at 400.132 MHz) analyses were performed. In the latter case, amino-PVA was 
solubilized in deuterium oxide at the concentration of 30.0 mg/mL. 
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1H NMR (400 MHz, D2O, 25°C, δ): 0.84 (br, CH2-CH-CH2-C), 1.63 (br, N(CH3)2-CH2-CH2 and CH3-C-
CO), 1.81 (br, CH3-CO), 2.28 (N(CH3)2), 2.46 (br, N(CH3)2-CH2-CH2), 3.02 (br, CH2-NH-CO and CH-
O-CO). 
 
FT-IR spectroscopy is a technique based on the absorption in the infrared region (IR) that arises 
predominantly from excitation of molecular vibrations. The IR region covers wavelengths from 
approximately 800 nm to 1 mm. It is commonly divided into three sub-regions: near IR, from the 
visible to 2.5 μm; mid IR, from 2.5 to 25 μm; and far IR, beyond 25 μm. Our analysis was 
performed between 700 and 4000 nm, in between NIR and mid IR. The IR spectrum derived from 
FT-IR analysis gave evidence on the molecular structures. In fact, each peak can be related to 
symmetric and antisymmetric stretching, scissoring, rocking, wagging and twisting of atoms bond 
to each other. Correct spectrum interpretation allows the comprehension of different groups 
present in the molecular structure.  
Nuclear magnetic resonance spectroscopy is another powerful source of information on the 
structure and dynamics of molecules. Almost every molecule has at least one magnetic nucleus 
already in place, sensitive to its surroundings and weakly interacting with them. As such, nuclear 
spins are ideal probes of molecular properties at the atomic level. NMR spectra of molecules in 
liquids can give information on the intensities of individual resonances (which depend on the 
number of nuclei responsible), chemical shifts (the interaction of nuclear spins with an applied 
magnetic field), spin–spin coupling (their interactions with one another), spin relaxation (the 
restoration of thermal equilibrium), and chemical exchange (the effects of conformational and 
chemical equilibria). 
 
4.2.2 Synthesis of PLGA nanoparticles with amino-PVA 
 
The A-OW-ctr sample was synthesized by emulsifying 300 µL of PLGA in ethyl acetate (50.0 
mg/mL) with 600 µL of surfactant (amino-PVA 1.0% w/v or a mix of PVA/amino-PVA). This mixture 
was sonicated (30% amplitude, 15 sec, ice bath) and the obtained oil-in-water emulsion was 
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dispersed in 60.0 mL of PVA 0.3% w/v. The organic solvent was evaporated under magnetic 
stirring for 3.5 h.  
In a different way, the A-ctr sample were prepared by adding at 300 µL of PLGA solution (50.0 
mg/mL) in ethyl acetate 45 µL of PBS 0.1X. The mixture was sonicated at 30% amplitude for 15 sec 
in ice bath to obtain the primary water-in-oil emulsion. This emulsion was then added to 600 µL of 
surfactant and ultrasounds were applied with the same protocol described above, to achieve the 
multiple water-in-oil-in-water (WOW) emulsion. Finally, the WOW emulsion was diluted in the 
dispersing phase (60.0 mL PVA 0.3% w/v) and the organic solvent was evaporated via magnetic 
stirring for 3.5 h.  
 
4.2.3 Encapsulation of hydrophobic molecule: curcumin 
 
Curcumin was added as hydrophobic molecule in both OW (A-OW-cur) and WOW (A-cur) samples. 
A final concentration of 5.0 mg/mL of the drug was obtained by dissolving 1.5 mg of powder in 
the oil phase.  
 
4.2.4 Encapsulation of hydrophilic molecules: fib-647, FITC 
 
For WOW synthesis A-fib, fib-647 was added at the concentration of 1.0 µM as model molecule. 
Differently, in A-FITC sample the inner aqueous NPs core was composed by a 0.1 mg/mL solution 
of FITC, as model fluorophore.  
 
4.2.5 Encapsulation of both hydrophilic and hydrophobic molecules: curcumin and fib-647 
 
The ability of the WOW syntheses to encapsulate simultaneously molecules with different 
characteristics was tested by adding both curcumin and Fib-647 (A-fib-cur). In this case, the 
synthetic procedure was similar to those for A-fib, with the addition of 1.5 mg of curcumin at the 
oil phase. 
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4.3 Synthesis of PLGA NPs with calcium stearate 
 
C-OW-ctr was obtained by OW method. Firstly, 15 mg of PLGA and 3.0 mg of calcium stearate 
were dissolved in 300 μL of Span® 60 (1.0 mg/mL in ethyl acetate). The solution was then 
emulsified with 600 μL of polysorbate 60 (1.6 mg/mL) by ultrasound (30% amplitude, 15 sec, ice 
bath). The so formed emulsion was diluted with 30.0 mL of D-mannitol 5% w/v and the organic 
solvent was evaporated via magnetic stirring for 3.5 h.  
In a different way, a two step procedure was used to obtain C-ctr, with an inner aqueous core. 
First, 45 µL of PBS 0.1X were added to the oil phase (300 µL of ethyl acetate, with PLGA 50.0 
mg/mL, Span® 60 2.0 mg/mL, calcium stearate 10.0 mg/mL) and sonicated at 30% amplitude for 
15 sec in ice bath, to obtain the primary water-in-oil emulsion. This emulsion was then added to 
600 μL of polysorbate 60 3.2 mg/mL and sonicated using the same protocol described above, to 
achieve the multiple water-in-oil-in-water emulsion. Finally, the WOW emulsion was diluted in the 
dispersing phase (30 mL D-mannitol 5.0% w/v) and the organic solvent was evaporated via 
magnetic stirring for 3.5 h.  
 
 
4.3.1 Encapsulation of hydrophobic molecule: curcumin 
 
Curcumin was added in both OW (C-OW-cur) and WOW (C-cur) samples. In details, 1.5 mg of 
powder were dissolved in the oil phase to obtain a final drug concentration of 5.0 mg/mL. 
 
 
4.3.2 Encapsulation of hydrophilic molecules: fib-647, FITC 
 
For WOW synthesis (C-fib), fibrinogen linked with Alexa647® (fib-647) was added as hydrophilic 
model molecule at the concentration of 1.0 µM. Differently, in sample C-FITC the inner aqueous 
NPs core was composed by a 0.1 mg/mL solution of FITC, as model fluorophore.  
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4.3.3 Encapsulation of both hydrophilic and hydrophobic molecules: curcumin and fib-647 
 
The ability of the WOW synthesis to simultaneously encapsulate two molecules with different 
characteristics was tested by concurrent employment of curcumin and Fib-647 (C-fib-cur). In this 
case, synthetic procedure was similar to those for C-fib, but 1.5 mg of curcumin were additionally 
added at the oil phase. 
 
4.4 Nanoparticles recollection and purification 
 
For all the described syntheses, NPs were collected and washed with four cycles of centrifugation 
at 15,000 g for 20 min at 4°C, in order to remove exciding surfactant, as well as not encapsulated 
drugs and biomacromolecules. 
 
5. Nanoparticle characterization 
 
5.1 Dynamic Light Scattering (DLS) 
 
Immediately after synthesis, the PLGA NPs were thoroughly characterized by Dynamic Light 
Scattering (DLS) to assess their size and ζ-potential. To this aim, the PLGA NPs pellet was diluted 1 
to 1000 in MilliQ water. Measurements were performed with a Malvern Ζetasizer Nano ZS90 
instrument operating with a light source wavelength of 633 nm and a fixed scattering angle of 90°. 
All the analyses were run in triplicate. 
DLS is a technique based on light scattering that measured hydrodynamic diameter of object 
ranging from few nm up to 5-6 µm. It is based on the statistical analysis of the scattered light 
fluctuations in samples of colloidal solution. In fact, particles in suspension undergo Brownian 
motion caused by thermally induced collisions between the suspended particles and the solvent 
molecules. These movements are strongly related to the particles size: the smaller the particles, 
the faster their movements. In this context, particles illuminated with a laser scatter light with an 
intensity that vary overtime. The rate of this variation is related to the translational diffusion 
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coefficient (D), thus making possible to calculate the particles hydrodynamic radius (Rh) through 
the Stokes-Einstein equation: 
 
𝑅ℎ =  
𝐾𝑏𝑇
3𝜋𝜂𝐷
 
 
where Kbis the Boltzmann constant, T is the temperature express in Kelvin, and η is the solvent 
viscosity. 
 
The diameter obtained by this technique is that of a sphere with the same translational diffusion 
coefficient of the particle being measured. It is called hydrodynamic diameter because it refers to 
the way a particle diffuses within a fluid.  
DLS analysis results in a statistical distribution of the intensity fluctuations generated by a number 
of particles. Therefore, NPs size is express as the mean of a size distribution and its polydispersity 
index (pdI). 
A schematic diagram of the DLS apparatus is given in Fig.11. 
 
 
Fig.11. Schematic layout of dynamic light scattering (DLS) setup (the diagram is not to scale). 
Panel A - The sample is illuminated and the scattered light intensity is detected at 90° from the 
laser source, and sent to the autocorrelator. The generated autocorrelator function (correlogram) 
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is then used to calculate the diffusion coefficient. Panel B - Light scattering is the alteration of the 
direction and intensity of a light beam that strikes an object. 
 
Since the scattered signal can be saturated, the instrument take advantage on attenuation that 
can vary from 1 up to 11, where 11 indicates no attenuation and 1 maximum attenuation. 
Accordingly, the scattered intensity and the mean count rate (i.e. the mean of the detected 
photons) recorded during DLS measurements are correct by the attenuator factor. Conversely, by 
properly correct the mean count rate for the attenuation factor, the Derived Count Rate (DCR) 
can be calculated. The DCR represents the intensity that would have been measured if no 
saturation occurred. In this thesis, the DCR was used to compare different analyses made on the 
same sample during time.  
With the DLS apparatus it was possible to measure also NPs surface properties in terms of 
electrokinetic potential (ζ-potential or surface charge). Fig.12 illustrated the electrical double 
layer that surrounds stable colloidal particles, and the ζ-potential meaning.  
 
 
Fig.12. Schematic representation of the electrical double layer that surrounds stable colloidal 
particles. 
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Charged groups present in the polymer or in the surfactant used for NPs synthesis are usually 
present on the NPs surface. These electric charges affect the ions distribution in the surrounding 
interfacial region, resulting in an increased concentration of counter ions close to the NPs surface 
(Stern layer). Around each particle, an electrical double layer is then formed. Moreover, a second 
diffuse layer (Gouy-Chapman layer) of mobile ions is formed on top of the rigid sphere and is 
generally responsible for the colloid stability of the system. Ions in this outer layer can be 
displaced as the particle moves through the liquid, whereas the notional boundary (slipping 
plane) within the diffuse layer represents a stable entity between ions and particle. When a 
voltage is applied to this particle solution, the charge at the slipping plane is termed zeta (ζ) 
potential. This is a reliable index to assess NPs surface properties as well as their stability. In fact, 
ζ-potential values minor than -20.0 mV or higher than +20.0 mV usually ensure electrostatic 
repulsion between NPs103–105. 
DLS apparatus allows to measure particle mobility by electrophoresis. A Laser Doppler 
Velocimeter applies an electrical field of known strength across the sample, through which a laser 
passed. Charged particles in the dispersion will migrate to the oppositely charged electrode with a 
velocity proportional to the magnitude of the ζ-potential. The measured electrophoretic mobility 
(μe) is related to the ζ-potential by the Henry equation: 
 
µ𝑒 =
2𝜀𝜁𝑓(𝐾𝑎)
3µ
 
 
where ε is the dielectric constant of the sample, η is the viscosity of the liquid phase, ζ is the ζ-
potential, and f(Ka) is the Henry’s function.  
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5.2 Microscopies 
 
5.2.1 Confocal laser scanning microscopy 
 
To investigate the encapsulation of the model drugs, analyses were performed by confocal laser 
scanning microscopy (Leica TCS SP5 AOBS, Leica Microsystems GmbH) microscopy, thanks to the 
optical properties of the selected model molecules. Before analyses, PLGA NPs were purified. The 
NPs pellet was resuspended in MilliQ water (1:200) and dialyzed for three h using a Spectrapor 
membrane (cut off 100 KDa). The suspensions were then additionally diluted 1:500 and 5.0 µL of 
the final samples were left drying on a glass slide.  
The confocal analyses were obtained with the laser passing through an objective lens 63x, oil 
immersion, numerical aperture 1.4. 
Excitation was obtained by different laser, depending on the fluorophore characteristics, as can 
be seen in Table1Table3 (for IgG-Cy3 and CD4-FITC see Appendix 1 page 124). 
 
Fluorophore Laser Excitation wavelength (nm) 
Curcumin Argon 458 
IgG-488 Argon 488 
IgG-Cy3 Diode 561 
CD4-FITC Argon 488 
Fib-647 Helium-neon 647 
FITC Argon 488 
Table3. Laser and excitation wavelength (nm) used for confocal microscope analysis. 
 
Confocal microscopy is an optical imaging technique based mainly on fluorescence detection. 
Main advantage in using confocal with respect to other microscopy techniques is related to the 
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presence of a spatial pinhole placed at the confocal plane of the lens. This allows eliminating out-
of-focus light thus increasing optical resolution and contrast. 
 
To better resolve the obtained fluorescent NPs132, a Leica TCS SP8 microscope equipped with a 
gated-stimulated emission depletion (STED) module (Leica Microsystems GmbH, Germany) an 
HCX PL APO 100x/1.4 OIL STED ORANGE objective, a white light laser (WLL) source, and a 592 nm 
depletion laser was additionally employed. The STED images were acquired using the hybrid 
detectors with a pixel size of 25 nm. To prepare samples for STED analysis, after the purification 
steps describe above PLGA NPs suspensions were deposited onto a glass coverslip and left drying 
for 1h. One drop of ProLong® Gold was then added, another glass coverslip was placed above and 
samples were allowed to cure in the dark for 24 h. 
 
5.2.2 Scanning Electron Microscopy 
 
Scanning electron microscopy (SEM, Zeiss Sigma, Carl Zeiss NTS GmbH) was used to assess PLGA 
NPs morphology. Before analyses, PLGA NPs were purified with the same procedure described for 
confocal analysis samples in paragraph 5.2.1. In this case, 5.0 µL of the final samples were left 
drying on a silicon support. Before the SEM analysis, samples were placed in a vacuum pump for 2 
h. All of the SEM images were acquired with an accelerating voltage of 1 kV. In some cases, 
dimensional distribution of PLGA NPs was calculated, by meaning of the open source software 
Image J. 
 
A scanning electron microscope scans the samples with a focused beam of electrons that interact 
with sample atoms. This produces a variety of signal that can be detected and elaborated to 
return samples surface topography and composition, as well as samples morphology. In fact, by 
the combination of beam’s position and detected signal it is possible to obtain high resolution 
images. 
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6. Degradation studies 
 
To assess NPs degradation, PBS 1X at pH 7.4 was chosen as medium mimicking physiological 
conditions (dilution 1 to 1000) and samples were incubated at 37°C under continuous rotation 
(100 rpm). At determined time points, each sample was analyzed by DLS and/or SPES.  
 
6.1 Dynamic Light Scattering 
 
Several parameters including the absolute number of detected photons (i.e. the derived count 
rate, DCR) as well as size and correlogram shape were considered to establish the NPs stability 
during time. 
Moreover, DLS was used to assess PLGA NPs stability in medium at different pH values. 
 
6.2 Single Particle Extinction and Scattering (SPES) 
 
Before performing the degradation studies with Single Particle Extinction and Scattering (SPES), 
each PLGA NPs batch was added with 1.0% w/v D-mannitol as cryoprotectant and lyophilized. For 
comparison purpose, same treatment was reserved before DLS analysis. Analysis by SPES was run 
after an additional dilution 1 to 500 in PBS with respect to the 1 to 1000 dilutions for DLS analysis. 
 
SPES is a method for the characterization of NPs that is based on the analysis of the forward 
scattered fields133–135. A schematic diagram of the SPES apparatus is given in Fig.13. 
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Fig.13. Schematic representation of the SPES apparatus. Particles (C) are driven through a tightly 
focused laser beam (B); the scattered (E) and transmitted (D) fields interfere (F) onto a segmented 
detector (G). 
 
A lens (A) focuses a laser beam (B) into a flow cell (C), through which the sample is driven at 
constant speed. The superposition of the faint scattered light by each single nanoparticle (E) and 
the intense transmitted field (D) generates time dependent interference patterns (F) on a 
segmented photodetector (G), thus generating corresponding electrical signals. The light intensity 
modulations due to the interference are proportional to the amplitude of the forward scattered 
field of the single particles driven through the scattering volume. In addition, the power reduction 
of the entire beam, which rigorously gives the total extinction cross section of the particles, 
provides enough information for a complete characterization of the scattered field.  
A dedicated data analysis recovers the basic features of the complex scattered field in terms of its 
real and imaginary parts. In this way SPES can be employed to realize the complex field approach 
and to precisely determine two independent parameters for each particle: the extinction cross 
section and the optical thickness of the particle. The latter is defined as the product  
C
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E
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G
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s = d (m - 1) 
 
where d is the particle diameter and m is the refractive index relative to the surrounding medium. 
Especially for spherical NPs, from the combination of the two measured parameters, it is possible 
to estimate the average refractive index of each particle, thus determining the actual particle size 
with a better accuracy compared to traditional scattering methods. The single particle approach 
guarantees higher accuracy and resolution, avoiding artifacts due to the invention algorithms 
required for the analysis of the correlation function as in the case of DLS. SPES method is 
particularly promising for polydisperse samples, as well as in cases of particles mixture with 
different compositions and shapes. Finally, single particle approach is able to discriminate 
between NPs and impurities that present different refractive index, thus allowing analysis of 
suspensions in complex media (i.e. serum, plasma, cells growth medium).  
In the case of PLGA NPs degradation studies, SPES was selected as additional analytical technique. 
In fact, during the degradation process NPs relative refractive index is supposed to decrease, even 
if this not necessarily results in a variation in NPs size. This means that SPES can observe variation 
in the PLGA NPs that a classically used technique, such as DLS, is not able to measure.  
 
7. Release studies 
 
In vitro drug release of model drugs, such as curcumin and fib-647, was evaluated by the 
dissolution technique136 and followed through spectrofluorimetry (FluoroMax 4, Horiba, 
JobinYvon).  
The release experiments were performed by suspending five µL of the NPs pellet in 5.0 mL of PBS 
1X with 5.0 w/v D-mannitol and incubating at 37°C under continuous rotation (100 rpm). At 
specific time points (0, 2, 4, 7, 24, 168, 336 h) 1.0 mL was taken and centrifuged at 15,000 g for 15 
min (25°C). In order to maintain the NPs concentration, the resultant pellet was resuspended in 
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1.0 mL of fresh medium and added again at the original samples. Instead, the supernatants 
followed different fate dependently on the nature of the model drugs.  
Released curcumin was extracted by means of chloroform and analyzed by spectrofluorometer 
(excitation 450 nm, emission 460-600 nm) after appropriate dilution.  
Differently, released fib-647 was directly analyzed in the aqueous phase, without extraction 
(excitation 647 nm, emission 660-800 nm).  
Samples were run in triplicate and data are presented as mean±standard deviation (SD).  
 
 
Fluorescence is a form of luminescence, which is defined as the emission of light from any 
substance. In particular, fluorescence is related to the emission of photons from singlet-excited 
states. The electron in the excited orbital is paired (of opposite sign) to the second electron in the 
ground-state orbital. Return to the ground state is spin-allowed and occurs rapidly by emission of 
a photon. The emission rates of fluorescence are typically 108 s−1, so that a typical fluorescence 
lifetime is near 10 nsec. Basic fluorescence spectral data are generally presented as emission 
spectra. The intensities and wavelengths of these spectra can vary widely depending on the 
chemical structure of the fluorophore and the solvent in which it is dissolved. 
 
7.1 Calibration curve for curcumin 
 
 
In order to perform a quantitative analysis of the cumulant release, calibration curves were 
obtained. 
Curcumin calibration curve were prepared by starting from a stock solution at 50.0 pg/mL in 
chloroform. Different concentrations were tested: 40.0, 35.0, 30.0, 25.0, 20.0, 15.0, 10.0, 5.0, and 
0 pg/mL.The obtained calibration curve was linear with a Pearson’s coefficient of 0.99923 and 
defined by the equation y=28442.11*x+38264.10 (Fig. 14, n=5).  
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Fig. 14. Curcumin calibration curve. Data are means±SD (n=5) 
 
 
 
7.2 Calibration curve for fib-647 
 
Differently, for the fib-647 calibration curve, aqueous 10.0 nM solution was prepared as a stock 
and the tested concentrations were: 7.0, 6.0, 5.0, 4.0, 3.0, 2.0, 1.0, 0.5, and 0 nM. In this case, 
calibration curve had a Pearson’s coefficient of 0.99396 and was defined by the equation 
y=171474.93*x-58771.31 (Fig. 15, n=5) 
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Fig. 15. Fib-647 calibration curve. Data are means±SD (n=5) 
 
 
 
8. Surface modifications: protein corona and D-mannose 
 
In order to decorate NPs surface with molecules recognized by TAMs and macrophages, NPs were 
incubated with a solution of 10.0% v/v FBS and 20.0% w/v D-mannose (FBSM). NPs were 
suspended in the medium and incubated for 24 h at 37°C under mild rotation (100 rpm). Samples 
purification from exceeding macromolecules was performed by centrifugation (five cycles at 
15,000 g, 15 min, 4°C). For comparison, also different conditions were tested, namely 10.0% v/v 
FBS without D-mannose (FBS), 100% FBS with (100FBSM) and without (100FBS) 20.0% w/v D-
mannose, 20.0% w/v D-mannose (M).  
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8.1 Dynamic Light Scattering 
 
Analyses to assess surface functionalization were performed by means of DLS in terms of size and 
ζ-potential. 
 
8.2 X-ray photoelectron spectroscopy (XPS) 
 
In addition, X-ray photoelectron spectroscopy (XPS) spectra were analyzed on samples with a D-
mannose decorated surface. NPs were purified by dialysis as described in the 5.2.1 Confocal laser 
scanning microscopy page 58 in the Materials and Methods section. The NPs pellet was 
resuspended in MilliQ water (1:200) and dialyzed for three h using a Spectrapor membrane (cut 
off 100 KDa). The suspensions were then additionally diluted 1:500 and the final samples were left 
drying on a silicon support, so that surface was completely covered by NPs. Analyses were run 
with a UHV apparatus Leybold LH 10/12, X-ray source Mg K = 1253.6 eV, Pass Energy = 30 eV, 
Energy resolution 0.7 eV. 
Photoelectron spectroscopy is a molecular spectroscopic method based on photoionization. If an 
atom or molecule is irradiated with photons of energy higher than the ionization energy of the 
particle, ionization may occur. Types of photoelectron spectrometers are distinguished on the 
basis of the energy of the radiation sources. When X-ray photons are used for core electron 
ionizations, photoelectron experiments are called X-ray photoelectron spectroscopy, XPS. This 
technique can provide information about the elemental composition, empirical formula, chemical 
state and electronic state of the elements that exist within a material. 
 
9. In vitro cytotoxicity studies 
 
For cytotoxicity studies, RAW264.7 (American Type Culture Collection, ATCC) murine 
macrophages were selected as a model cell line. Cells were grown overnight in Dulbecco minimal 
essential medium (DMEM) containing 10.0% v/v fetal bovine serum (FBS) and 2 mM glutamine. 
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In addition, primary culture of mouse bone marrow-derived macrophages was investigated. 
Female Fvb/Hd mice were sacrificed with CO2 and bones were collected. After cleaning from 
exceeding muscles and ligaments, bones were smashed with a pestle, cleaned with PBS and the 
bone marrow was filtered in a 70 µm cell strainer. Red blood cells were removed with NaCl 
gradient and remaining cells were suspended in their grown medium (high glucose DMEM 
supplemented with 20.0% v/v lowendotoxin fetal bovine serum, 30.0% v/v L929-conditioned 
medium, 1.0% v/v glutamine, 1.0% v/v Pen/Strep, 0.5% v/v sodium pyruvate, and 0.1% v/v b-
mercaptoethanol). Cultures were fed with 2.5 mL of fresh medium every 2 days. Stimulations 
were carried out at day seven. 
To assess PLGA NPs cytocompatibility a [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] (MTT) test (Roche) was performed. Macrophages (both RAW264.7 and bone marrow-
derived) were plated at a cell density of 1 x 106 cells/mL into 96-well plate. After appropriate 
proliferation at 37°C in 5% CO2 and 98% air-humidified, cells were treated with 10 µL of different 
PLGA NPs suspensions, as well as positive (EtOH, DMSO, as cytotoxic agents) and negative (PBS) 
controls. Two dilutions in PBS 1X pH 7.4 were tested, namely 1 to 10 and 1 to 100. Cytotoxicity 
test was conducted by following manufacturer instruction after 24 h. Colorimetric analysis of the 
formazan product was performed with a TECAN sunrise spectrophotometer at 550 nm. 
The MTT reduction assay was the first homogeneous cell viability assay developed for a 96-well 
format. The MTT substrate is prepared in a physiologically balanced solution, added to cells in 
culture and incubated for 4 h. Viable cells with active metabolism convert MTT into a purple 
colored formazan product with an absorbance maximum near 570 nm. Ability to convert MTT into 
formazan is conversely lost in died cells, thus color formation is a valuable marker for viable cells. 
The quantity of formazan, presumably proportional to the number of viable cells, is measured by 
recording changes in absorbance using a plate reading spectrophotometer. 
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Results and discussion 
 
1. PLGA NPs synthesis with PVA: parameters investigation 
 
Selected technique for PLGA NPs synthesis was the emulsion-solvent evaporation method. This 
synthesis allows the encapsulation of hydrophobic and/or hydrophilic molecules by properly 
varying synthetic parameters. In particular, attention was focused on single emulsion (oil-in-
water, OW) synthesis to encapsulate the hydrophobic drug curcumin, while double emulsion 
(water-in-oil-in-water, WOW) method was employed for biomacromolecules, such as RNA or 
model antibodies.  
In the optimization of the synthetic parameters, the well-known surfactant PVA was selected to 
study the PLGA behavior in both OW and WOW synthesis. Accordingly, experiments were run by 
systematically change different key steps of the synthetic procedure (Fig.16). A brief summary of 
the experimental conditions employed in NPs synthesis is reported in Table4.  
 
Parameter Starting condition 
PLGA Molecular Weight 38-54 KDa 
PLGA concentration 50.0 mg/mL 
Organic solvent Ethyl acetate 
Primary aqueous phase (for WOW synthesis) Saline solution composed of 0.1 M sodium 
phosphate, 0.1 M NaCl and 5.0 mM sodium 
azide (pH 8.3) 
Surfactant PVA 31 KDa, 1.0% w/v 
Ultrasounds application 20% amplitude 
Cooling bath Ice bath 
Freeze-drying No freeze-drying 
Table4. Summary of PLGA NPs synthetic conditions in the initial formulation. To note, each 
parameter was varied while keeping all other parameters constant. 
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Fig.16. Schematic representation of both single and double emulsion syntheses. Letters 
underlined the different synthetic steps that were investigated. 
 
 
 
 
To select the most suitable formulations for drug/gene delivery, two main criteria were used. 
Firstly, NPs size and size distribution were examined, since they are closely related to NPs release 
properties94. In this regard, parameters as obtained by DLS analyses, such as z-average, peaks 
diameter size, polydispersity index (pdI) as well as the presence of more than one peak, were 
considered. Secondly, the NPs stability in a medium mimicking physiological conditions (PBS 1X pH 
7.4) was investigated.  
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1.1 PLGA molecular weight 
 
PLGA applications in drug delivery are affected by its physical properties, and especially its MW87. 
Accordingly, PLGA with low (7-17 KDa), medium (38-54 KDa) and high (190-240 KDa) MW were 
tested. 
In OW synthesis, the higher the PLGA MW, the higher the NPs size and polydispersity (Table 5, 
samples 5A, 5B and 5C).  
 
 
 Synthesis MW (KDa) z-average (nm) Peaks (nm) PdI 
5A OW 7-17 315.7 328.0 0.170 
5B OW 38-54 328.7 321.4 0.220 
5C OW 190-240 437.9 384.8 0.311 
5D WOW 7-17 930.6 224.2+910.4 0.874 
5E WOW 38-54 484.1 228.1+1225 0.595 
5F WOW 190-240 445.2 334.1+5252 0.434 
Table 5. PLGA NPs obtained with different PLGA MW. NPs size was reported as z-average and 
peaks size, whereas size distribution was indicated by polydispersity index (pdI). 
 
 
On the contrary, in WOW synthesis, NPs presented very high polydispersity for all the tested PLGA 
MW, which strongly affected z-average reliability. Accordingly, to assess NPs diameter, the 
principal peak size was considered. No differences were observed between low and medium MW 
(samples 5D and 5E), while high MW PLGA originated larger NPs (sample 5F).  
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According to results reported in Table 5, PLGA having medium MW (38-54 KDa) was chosen for 
further investigation, because it provided NPs with promising features either by OW or WOW 
methods. 
 
1.2 Ultrasounds application 
 
In emulsion-solvent evaporation synthesis for PLGA NPs, it is necessary to provide energy by 
sonication or homogenization for inducing the formation of nano-sized droplets that in turn 
resulted in NPs after solvent evaporation. In this work, ultrasounds were applied by means of an 
ultrasonic probe. To note, no stable emulsion was obtained in the absence of ultrasounds 
application, since unstable replicates and a very high pdI (0.821) were observed by DLS. Low 
energy (20% amplitude) was sufficient to form emulsion; however, NPs showed high 
polydispersity (pdI 0.595) and size (z-average 484.1 nm). By increasing the amplitude up to 30%, 
NPs showed an improvement in polydispersity (pdI lower than 0.2) and a reduction in size up to 
300 nm. Accordingly, this amplitude was selected as the best one. 
 
 
 
1.3 PLGA concentration 
 
In WOW synthesis, when using PLGA 200.0 mg/mL, micron sized particles were obtained (z-
average 1,084 nm). Differently, if 5.0 mg/mL of PLGA were used, NPs had dimensions in the nano 
range (z-average 191.7 nm); however, they were not stable and degraded in less than 24 h. The 
corresponding OW synthesis with the same PLGA concentration (5.0 mg/mL), showed NPs with a 
slightly increase in size (z-average 223.6 nm). An intermediate concentration, namely 50.0 mg/mL, 
allowed the formation of PLGA NPs with size 233.8 nm for WOW (P1-ctr) and 223.3 nm for OW 
(P1-OW-ctr) syntheses. Notably, these formulations were found to be stable for one week in PBS 
at 37°C, therefore they were considered compatible with further applications in gene/drug 
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delivery. Consequently, the PLGA concentration of 50.0 mg/mL was selected for all the following 
experiments.  
 
1.4 Organic solvent 
 
One of the most commonly used solvent in PLGA NPs synthesis by emulsion-solvent evaporation 
method is dichloromethane (DCM). This solvent is completely immiscible with water, thus 
resulting suitable for emulsion formation. Although DCM presents a boiling point of 39.6°C that 
guarantees rapid evaporation, safety concerns are raised with its use. In this thesis a safer 
alternative to DCM, ethyl acetate, was investigated. While ethyl acetate traces are considered 
acceptable also in food137, chlorinate solvents such as DCM are carcinogenic and highly toxic138 
and it is fundamental that all the solvent molecules are eliminated from the final product. Besides 
the safety issues, experimental evidences showed that ethyl acetate was advantageous from the 
technological point of view. In fact, to obtain NPs of around 200 nm size in both OW and WOW 
synthesis, a reduced amount of PVA (1.0% w/v) and applied energy by ultrasounds (15 sec) were 
required by using ethyl acetate with respect to DCM (4.0% w/v PVA and 90 sec of ultrasounds). 
This is possibly due to the fact that, differently from DCM, ethyl acetate is slightly diffused in 
water139, thus helping interaction between the organic phase containing PLGA and the aqueous 
one. By taking into account the overall milder conditions in which the syntheses were performed, 
ethyl acetate was definitely selected as organic solvent for further experiments. 
 
1.5 Cooling bath temperature 
 
Mechanical waves in ultrasound application induced heating in the reaction mixture, thus 
potentially interfering with emulsion formation and stability. This is of particular importance in 
double emulsion synthesis, where biomacromolecules need to be loaded in the PLGA NPs. In fact, 
one of the major problems in protein and gene encapsulation is represented by harsh synthetic 
conditions that can degrade their structure. Another important issue in WOW synthesis is that the 
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primary aqueous phase tends to immediately disperse in the secondary aqueous phase, thus 
reducing the encapsulation efficiency. It was hypothesized that the use of a cooling bath during 
ultrasound application, having a temperature lower than the freezing point of the primary 
aqueous phase but higher than the freezing point of PLGA/ethyl acetate solution, may freeze and 
stabilize the first emulsion. Accordingly, improvement in NPs stability and encapsulation efficiency 
can be achieved. In this regard, different cooling baths were investigated: Ethylene glycol/CO2 (t = 
-15°C); CH3CN/CO2 (t = -41°C); ice bath (t = 0°C).  
Resulted syntheses are reported in Table 6. 
 
 Cooling bath Inner core z-average (nm) Peak (nm) PdI 
6A CH3CN/CO2 IgG1-488 237.6 248.2 0.031 
6B Ethylen glycol/CO2 H2O 231.8 244.2 0.048 
6C Ethylen glycol/CO2 IgG1-488 184.6 195.8 0.068 
6D Ice bath IgG1-488 233.8 245.3 0.026 
Table 6. Main DLS characteristics of PLGA NPs synthesized using different cooling baths. NPs size 
was reported as z-average and peaks size, whereas size distribution was indicated by 
polydispersity index (pdI). Being core-shell NPs, the inner core content is also reported. 
 
All the tested syntheses provided NPs with small size and narrow size distribution. Use of 
CH3CN/CO2 cooling bath was discarded, because during synthesis the first emulsion froze. This was 
unexpected, being the ethyl acetate freezing point -83.6°C. Evidently, the presence of PLGA in the 
solution changed the solvent properties, including the freezing point. Synthesis was possible 
because first emulsion immediately thawed when PVA was added as secondary aqueous phase.  
Confocal characterization (see paragraph 1.7 Encapsulation of hydrophilic molecules: IgG1-488, 
vegetal RNA page 76 of the Results and discussion section) of samples 6C and 6D showed 
fluorescent spots, indicating that both synthetic methods with ice bath and ethylene 
glycol/CO2were equally effective for encapsulating fluorescent molecules. Considering that ice 
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bath is cheaper and more easy-to-access with respect to the combination ethylene glycol/CO2, it 
was selected for all the following syntheses. 
 
1.6 Surfactant role 
 
1.6.1 PVA with low molecular weight and high hydrolysis rate 
 
Although PVA is a biocompatible polymer, its degradation requires long time140, and elimination 
from the organism generally occurs via renal excretion. In this context a molecule with small MW 
is supposed to be eliminated more easily. Accordingly, besides PVA 31 KDa, PVA 22 KDa was 
tested in PLGA NPs.  
In case of WOW synthesis, DLS analysis showed two peaks (320.8 nm and 1585 nm) and high 
polydispersity (pdI 0.371), indicating that this surfactant does not stabilize the emulsion. When 
OW synthesis was investigated, results were even worst and no stable emulsion was obtained 
(Fig. 17).  
 
 
Fig. 17. DLS size distribution for P-ctr synthesized with PVA 22 KDa. The analyses showed no NPs 
formation. Curves referred to three different technical replicates. 
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PVA 22 KDa was different from PVA 31 KDa not only for the MW but also for the degree of 
hydrolysis of the residual acetyl groups. In fact, while PVA 31 KDa had a partial hydrolysis (86.7-
88.7 mol%), PVA 22 KDa was totally hydrolyzed (98 mol%). Since the degree of hydrolysis in PVA 
has strong influence on the solubility and the swellability of the polymer, it can strongly influence 
the PVA behavior in water, thus interfering with its role in emulsion formation.  
According to these findings, PVA 31 KDa was used for all the following syntheses. 
 
1.6.2 PVA percentage 
 
Finally, the role of PVA as surfactant was investigated by testing PVA solutions with different w/v 
concentrations. As previously reported110,122,141–144, this was found to be the fundamental 
parameter for modulating NPs size and stability. 
In the absence of surfactant, even if the secondary WOW emulsion was milky, after solvent 
evaporation many aggregates were observed and DLS analysis showed unstable peaks and high 
polydispersity (Fig. 18). 
 
 
Fig. 18. DLS size distribution of PLGA NPs synthesized in the absence of surfactants. Curves 
referred to three different technical replicates. 
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Interestingly, this synthesis resulted in a -53.0 mV ζ-potential that was much more negative than 
the values found when PVA was employed, in which ζ-potential ranged from 24.6 to -31.0 mV.  
When the PVA concentration was varied from 1.0 to 0.1% w/v, the hydrodynamic diameter of NPs 
synthesized by OW ranged from 236.7 to 678.1 nm, respectively. Therefore, the more surfactant 
was added, the smaller the NPs were (Fig. 19). PdI ranged from 0.069 to 0.197, thus indicating 
very narrow polydispersity. 
 
 
Fig. 19. DLS size distribution with different amount of PVA. PLGA NPs size was found to be 
reduced by increasing the PVA concentration from 0.1 to 1.0% w/v. 
 
 
1.7 Encapsulation of hydrophilic molecules: IgG1-488, vegetal RNA 
 
The fluorescent labeled antibody IgG1-488 was encapsulated in P1-IgG-488, to evaluate WOW 
synthesis ability to encapsulate hydrophilic molecules in the inner aqueous core. As assessed by 
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confocal analysis (Fig. 20), fluorescent spots were detected in correspondence to nanoparticles as 
visualized in the contrast phase channel, thus indicating that the model molecule was actually 
internalized in the NPs.  
 
 
 
Fig. 20. Confocal characterization of P1-IgG-488 and P1-ctr. Fluorescent spots were 
correspondent to PLGA NPs, as assess by contrast phase images (panel A and B, sample 6C). Panel 
C referred to sample 6D. Panel D referred to the control (P1-ctr), where no fluorescence was 
observed. Scale bar is 5 µm. 
 
 
78 
 
As previously discussed, the use of siRNA to silence gene expression and normalize TAMs 
abnormal phenotype was considered a valuable alternative to TAMs depletion for cancer therapy. 
Accordingly, a mixture of RNA extracted by Arabidopsis (vegetal RNA) was encapsulated into PLGA 
NPs as model molecule. P1-vRNA showed a z-average of 197.5 nm and a very good 
monodispersity (pdI 0.022); therefore, they looked promising for future investigations.  
 
 
 
 
2. PLGA NPs synthesis with PVA: degradation studies 
 
PLGA NPs degradation properties are very important parameters in order to determine their 
potential for drug delivery. In fact, PLGA NPs must be stable in the bloodstream and fast degrade 
after endosome internalization, to release their content in the cell cytosol. Accordingly, PBS 1X at 
pH 7.4 was selected as medium mimicking physiological conditions and in particular bloodstream 
environment.  
Degradation experiments were monitored by DLS analysis and several parameters were 
considered to establish the NPs stability during time, including the absolute number of detected 
photons (i.e. the derived count rate, DCR) as well as size and correlogram shape.  
Fig. 21 showed that a very sharp decrease in the DCR occurred during the first 24-48 h for all the 
tested formulations, namely P1-vRNA, P1-IgG-488, P1-ctr and P1-OW-ctr. Then DCR decreased 
more slowly until a complete NPs degradation took place, as confirmed by the collection of an 
insufficient number of photons. Noteworthy, the more stable formulations were those with a 
core-shell structure and model molecules encapsulated. In fact, P1-IgG-488 and more evidently 
P1-vRNA were found to have the longest degradation time. Accordingly, these samples looked 
promising for potential in vitro and in vivo applications. 
 
79 
 
 
Fig. 21. Degradation profile of different PVA stabilized PLGA NPs. Notably, the degradation 
profiles of P1-OW-ctr and P1-ctr are partially superimposed. 
 
 
 
 
2.1 Stability at different pH values 
 
PLGA degradation mechanism takes place through hydrolysis of the ester bonds between the two 
monomers, lactic and glycolic acid. It is well established that ester bonds are susceptible to both 
acidic and basic conditions. P1-ctr stability was thus checked at different pH values, namely 8.5, 
7.5, 6.5, 5.5, 4.5 and 3.5. PBS 0.01X was used as buffer and pH was adjusted by sodium hydroxide 
or hydrochloric acid, as appropriate. 
At pH 7.5, degradation followed the trend already observed and presented in Fig. 21: DCR 
decreased quite rapidly during the first 24 h, then sample was stabilized for some days, until 
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complete degradation was observed at day 8. On the contrary, for all the other tested pH values, 
P1-ctr was stable for less than 24 h. This was partially expected, because pH variation accelerated 
the hydrolytic process. Since tumor environment is slightly more acidic with respect to the 
blood62,71,8 and endosomes show pH around 5-6, PLGA NPs able to degrade in these conditions are 
good candidates for tumor targeting and cytosolic release of their content.  
 
 
 
 
2.2 Stability after freeze drying 
 
Freeze-drying is a widely used procedure for improving the stability of different products including 
colloidal carriers. However, the process is relatively slow and expensive and its application is 
limited to products with a high added value145. P1-ctr and P1-IgG-488 were selected as candidates 
to assess if freeze-drying process was able to modulate PLGA NPs degradation. Both the samples 
were lyophilized with the addition of 5.0% w/v mannitol as cryoprotector.  
After resuspension in PBS 0.1 X pH 7.4, both P1-ctr and P1-IgG-488 underwent rapid degradation 
and DCR after 24 h was too low to complete the DLS analysis. Similar results were observed for 
PBS at different pH values, namely 6.5 and 5.5, as well as for 0.9% w/v NaCl.  
Notably, when degradation experiment (P1-ctr) was performed without rotation, a different 
profile was observed (Fig. 22). In fact, the sample showed a progressive degradation during time, 
lasting for three days. The forth day, DCR was too low, therefore no further DLS measurements 
were performed.  
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Fig. 22. P1-ctr degradation profile in static conditions. Before the analysis, samples were freeze-
dried with 1.0% w/v of D-mannitol as cryoprotectant. 
 
 
 
 
 
 
 
 
2.3 DLS vs. SPES 
 
Although DLS is an easy-to-use and powerful technique for the rapid characterization of NPs size, 
it does not provide any qualitative changes in terms of NPs composition and polymer degradation.  
For a more efficacious monitoring of NPs degradation, an alternative method (single particle 
optical extinction and scattering, SPES) was tested. To this purpose, NPs were synthesized with 
0.2% w/v PVA as surfactant by both OW and WOW emulsion method. Curcumin as hydrophobic 
molecule was encapsulated in solid (OW) NPs, while IgG1-488 was selected as model 
biomacromolecule for core-shell (WOW) systems.  
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Before performing dedicated analyses of degradation, PLGA NPs were thoroughly characterized 
by DLS. To note, the P0.2-OW-cur exhibited larger size with respect to the control (P0.2-OW-ctr) 
and the pdI values were low for both samples, indicating a narrow size distribution. The WOW 
synthesis (P0.2-IgG-488 and its control P0.2-ctr) resulted in NPs having smaller size and higher pdI 
than samples obtained by OW process. This is possibly due to the fact that ultrasound energy was 
applied to the systems twice (Table 7). 
 
 
 
Sample Z-ave (nm) Peak (nm) PdI ζ-potential 
P0.2-OW-cur 594.4 604.8 0.127 -30.8 
P0.2-OW-ctr 521.9 520.6 0.188 -30.6 
P0.2-IgG-488 475.3 416.0 0.310 -27.0 
P0.2-ctr 491.6 455.8 0.264 -24.3 
 
Table 7. The size profile of the tested PLGA NPs obtained by DLS analysis. 
 
 
 
Confocal microscopy characterization confirmed the presence of both the fluorophores (Fig. 23). 
In fact, fluorescence and transmitted light images showed co-localization, thus indicating that 
either curcumin or IgG1-488 were encapsulated into the PLGA NPs. On the contrary, no 
fluorescence was observed in the respective controls (P0.2-OW-ctr and P0.2-ctr). 
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Fig. 23. Confocal microscopy characterization for P0.2-OW-cur, P0.2-OW-ctr, P0.2-IgG-488 and 
P0.2-ctr. Samples were stabilized with 0.2% w/v of PVA as surfactant. For P0.2-OW-cur and P0.2-
IgG-488, fluorescent spots corresponding to curcumin and IgG-488, respectively, were found to 
co-localize with PLGA NPs observed in contrast phase images. No fluorescence was observed in 
their respective controls (P0.2-OW-ctr and P0.2-ctr) 
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In addition, samples morphology was assessed by Scanning Electron Microscopy (SEM) analysis. 
PLGA NPs was found to be round shape in all the tested samples, as shown in Fig. 24. SEM analysis 
additionally confirmed higher polydispersity of NPs obtained by WOW method with respect to 
solid (OW) NPs.  
 
 
Fig. 24. Scanning Electron Microscopy (SEM) characterization for P0.2-OW-cur, P0.2-OW-ctr, 
P0.2-IgG-488 and P0.2-ctr. For each synthesis, two different magnifications were reported. 
 
The dimensional distribution analysis on the acquired SEM images was performed using the Image 
J software. The size distribution (Fig. 25) was found to be slightly different to the one detected by 
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DLS, as expected because of the different parameter evaluated. In fact, DLS measures 
hydrodynamic diameter, while SEM analyses are performed on dry samples.  
 
 
 
Fig. 25. Dimensional distributions as assess by SEM images. Relative frequency (%) was obtained 
with Origin software after particle analysis on the SEM images by means of the free available 
software Image J. 
 
 
To investigate degradation properties, PLGA NPs were incubated in PBS, pH 7.4 at 37°C under mild 
rotation. Different conditions were tested, in particular PLGA NPs were freeze-dried with different 
amounts of either D-mannitol (1.0, 5.0, 10.0% w/v) or trehalose (1.0, 5.0, 10.0%) or a combination 
86 
 
of them (5.0% w/v D-mannitol and 5.0% w/v trehalose). As a control, PLGA NPs were also tested 
without lyophilization. Despite the variety of the tested conditions, no major differences were 
found in term of stability. Here the reported data are referred to samples freeze-dried with 1.0% 
w/v D-mannitol, being this condition representative of all the experimental set.  
After 24 h of incubation, DLS measurements indicated degradation of all the tested samples (Fig. 
26 and Table8), with particular evidence for core-shell NPs. This was assessed by the decrease in 
signal intensity, as express by DCR decline. In fact, during PLGA NPs degradation process a 
reduction of their relative refractive index occurred, thus reducing the total amount of the 
scattered light on which detection DLS analyses are based. 
 
 
 
Fig. 26. DLS size distributions for P0.2-OW-cur, P0.2-OW-ctr, P0.2-IgG-488 and P0.2-ctr at 
different time points. In samples obtained by double emulsion (P0.2-IgG-488 and P0.2-ctr), 
degradation was complete after 24 hr, therefore time points 48 hr and 72 hr are not reported. 
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Sample Time (h) z-average (nm) Peak (nm) PdI DCR (kcps) 
P0.2-OW-ctr 0 599.1 705.8 0.196 1359.2 
24 749.3 529.7 0.408 201.6 
48 1440.0 413.6 0.949 165.8 
72 1240.0 413.7 0.893 218.4 
P0.2-OW-cur 0 721.4 909.5 0.243 1062.2 
24 1478.0 571.1 0.780 162.3 
48 1309.0 548.1 0.766 185.6 
72 1228.0 442.5 0.825 179.1 
P0.2-ctr 0 624.0 625.4 0.360 738.1 
24 2412.0 78.8 1.000 5.6 
P0.2-IgG-488 0 708.0 588.8 0.524 313.8 
24 5560.0 0.0 0.864 3.4 
Table8. Main parameters obtained from DLS analysis at different time points. In samples obtained 
by double emulsion (P0.2-IgG-488 and P0.2-ctr), degradation was complete after 24 hr, therefore 
time points 48 hr and 72 hr are not reported. 
 
To overcome detection limit of DLS, an alternative approach based on SPES was used to 
characterize the NPs physical properties solution and their evolution during the degradation 
process. Details on how the SPES apparatus works can be found in paragraph 6.2 Single Particle 
Extinction and Scattering (SPES) page 60 of the Materials and methods section, as well as in 
literature133–135.  
SPES provided results in terms of particle size distribution (PSD) and refractive index distribution 
(RID). For the latter parameter, the average relative refractive index m is given. 
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PSD (Fig. 27) was found to be similar for all the tested samples. The mode values were 476 nm for 
P0.2-OW-ctr (panel A), 496 nm for P0.2-OW-cur (panel B), 456 nm for P0.2-ctr (panel C) and 456 
nm for P0.2-IgG-488 (panel D), respectively. 
 
 
Fig. 27. SPES particle size distribution (PSD) for P0.2-OW-cur, P0.2-OW-ctr, P0.2-IgG-488 and 
P0.2-ctr. Red lines indicated cumulative distribution. 
 
In a different way, some considerations can be done on the RID (Fig. 28). The red line, reported in 
all the graphs for comparison purpose, indicated the median value of the distribution for P0.2-
OW-ctr, m = 1.105. In this sample (panel A), refractive index showed a symmetric distribution, 
with the exception of a negligible tail at the lowest values. Blue lines in panel B, C and D indicated 
89 
 
the RID median values, namely m = 1.12, m = 1.085 and m = 1.081, for P0.2-OW-cur, P0.2-ctr and 
P0.2-IgG-488, respectively.  
 
 
 
Fig. 28. SPES refractive index distribution (RID) for P0.2-OW-cur, P0.2-OW-ctr, P0.2-IgG-488 and 
P0.2-ctr. Red lines referred to m value for P0.2-OW-ctr, while blue lines indicated m for the 
corresponding sample. 
 
As for P0.2-OW-ctr, also P0.2-OW-cur showed a symmetrical distribution for the refractive index 
values (panel B). Apparently, curcumin was encapsulated uniformly in all the PLGA NPs, as 
expected from an OW synthesis, in which the drug is homogeneously mixed with the polymer in 
the organic phase. Confocal analyses presented in Fig. 23additionally supported the results.  
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On the contrary, for sample P0.2-ctr (Fig. 28, panel C) RID was found to be shifted to small values. 
This was compatible with NPs core-shell structure. In fact, the presence of the aqueous inner core 
reduced the polarizability of the whole NPs, thus determining a reduction of the effective 
refractive index m. Noteworthy, for this sample a pronounced skewness was evident in the RID 
graph, indicating that the refractive index was spread over a more extended range, associable 
with the presence of drops with different size inside the NPs.  
Samples undergoing degradation in PBS were analyzed to compare SPES and DLS results. Fig. 29 
reported RID and PSD for P0.2-OW-ctr after incubation for 24 h. Similar considerations were done 
for all the other samples. 
 
 
Fig. 29. SPES refractive index distribution (RID) and particle size distribution (PSD) for P0.2-OW-
ctr after 24 h degradation. Results obtained for the degradation of P0.2-OW-ctr after 24 h 
incubation at 37°C with PBS. 
 
Red line in panel A represented the average m as detected at time 0, while the blue line referred 
to the distribution detected after 24 h of the degradation study. As can be seen, m was 
appreciably smaller than that measured before incubation. Graphs also evidenced a skewed 
distribution, indicating the presence of NPs with different degree of compactness. Moreover, the 
PSD (panel B) showed an increase in NPs size, as indicated by the 515 nm mode value.  
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According to these results, the SPES method was found to have a good sensibility to the NPs 
changes after 24 h thanks to the peculiar forward scattering scheme adopted. During the 
degradation process, NPs were found to increase their size while reducing their refractive index. 
For DLS, both these conditions are responsible for the reduction of the scattered light and 
consequently detrimental on the instrumental performances. On the contrary, the peculiar 
forward scattering scheme on which the SPES apparatus is based is able to take advantages on the 
two phenomena and provide valuable results.  
 
 
 
 
 
 
 
 
 
 
3. Amine-modified PVA as a novel surfactant to modulate size and surface charge 
of PLGA NPs 
 
A major drawback relative to PVA employment in PLGA NPs synthesis is the final negative charge 
on the NPs surface. In particular, as reported in paragraph 1.6.2 PVA percentage page 75 in the 
Results and Discussion section, the ζ-potential values ranged from -24.6 to -31.0 mV for PVA 
synthesized samples. Such values are effective for colloidal stability, because they guarantee PLGA 
NPs repulsion. However, a negative surface charge prevents the nanoparticles from escaping the 
endosomes after cell internalization. 
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3.1 Synthesis and characterization of amino-PVA 
 
By taking advantage of the PVA backbone, a new polymer (amino-PVA) was synthesized starting 
from two different monomers, vinyl acetate and DMAPMA. The first one, that is the monomer 
used for the synthesis of PVA, constituted the main chemical structure. By adding DMAPMA as 
monomer, tertiary amine groups were inserted in the surfactant as side groups. This provided the 
polymer with a positive charge (+19.5 mV), while avoiding the toxic potential of primary amines. 
Amino-PVA chemical structure can be seen in Fig. 30.  
 
 
 
 
Fig. 30. Chemical structure of the new synthesized polymer, amino-PVA. 
 
 
 
In order to assess molecular structure and monomer ratio in the final polymer, chemical 
characterization was performed by means of 1HNMR and FT-IR spectroscopy (Fig. 31). FT-IR 
analysis (panel B) showed great similarity between the amino-PVA spectrum and the one of 
DMAPMA. On the contrary, 1HNMR analysis was more informative. As could be seen in the 
reported spectrum (panel A), chemical groups peculiar for both the two single starting monomers 
were present. In particular, a vinyl acetate/DMAPMA molar ratio of 0.26 was calculated, based on 
peaks at 1.81 ppm and 2.28 ppm which were related to vinyl acetate and DMAPMA, respectively. 
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This indicated that both the monomer participated at the polymerization process and the 
product’s chemical structure was in good accordance with the hypothesized one.  
 
 
 
 
Fig. 31. 1HNMR spectrum (panel A) and FT-IR spectra (panel B) of amino-PVA. 
 
 
 
 
3.2 Synthesis of PLGA nanoparticles with amino-PVA 
 
The potential of amino-PVA as a surfactant alternative to PVA was explored for PLGA NPs 
synthesis. Different surfactant concentrations were tested (from 1.0 to 5.0%), however micron 
sized particles were obtained. DLS analyses indicated very polydisperse population, in some cases 
with more than one NPs peaks. In addition, the surface charge was highly positive (+40.0 mV). 
This value is considered too high, because anion serum proteins can be strongly adsorbed onto 
NPs surfaces with consequent risk of opsonization and elimination from the organism.  
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An effective approach to obtain NPs with reduced size and positive charge consisted in using 
different combinations of PVA and amino-PVA. Notably, the PVA was found to reduce NPs 
diameter when used in combination with amino-PVA, although to a lesser extent with respect to 
PVA alone. In fact, as shown in Table 9, the more PVA was added, the smaller NPs were obtained. 
 
 PVA/amino-PVA Z-ave (nm)  Main peak (nm)  pdI ζ-potential 
9A 1/0 223.3  236.7  0.072  -29.9 
9B 0.975/0.025 259.3  280.3  0.103  20.0  
9C 0.95/0.05 314.9  336.2  0.048  38.1  
9D 0.9/0.1 377.3  434.2  0.113  32.9  
9E 0.7/0.3 552.9  646.8  0.144  45.3  
9F 0/1 978.8  1225  0.180  39.4  
Table 9. DLS size distribution and ζ-potential of PLGA NPs synthesized by mixing PVA and amino-
PVA at different concentrations with OW synthesis. Control experiments were performed by using 
either PVA or amino-PVA alone. 
 
 
While the PVA concentration was found to modulate the NPs size, the amino-PVA played an 
important role in determining the NPs surface properties. In particular, a very small quantity 
(0.025%) of amino-PVA was sufficient to provide the NPs surface with a mild positive charge (ζ-
potential of +20.0 mV). In this way colloidal stability was guaranteed, while avoiding possible toxic 
effects due to a high positive charge. 
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3.2.1 Encapsulation of hydrophilic molecules: FITC, fib-647 
 
Similar results in terms of size distribution and ζ-potential were obtained when WOW syntheses 
were performed. As can be seen in Table 10, NPs size was higher than using the OW procedure 
(sample 10A vs. sample 9A, sample 10C vs. sample 9B).  
 
 
 
 PVA/amino-PVA  Inner core Z-ave (nm) Main peak (nm) pdI ζ-potential 
10A 1/0 PBS 0.1X 292.2 314.9 0.130 -31.0 
10B 1/0 FITC 271.5 314.2 0.126 -20.2 
10C 0.975/0.025 PBS 0.1X 286.8 315.1 0.104 +20.1 
10D 0.975/0.025 FITC 307.6 338.3 0.154 +19.2 
10E 0.975/0.025 Fib-647 345.4 377.1 0.119 +27.0 
Table 10. DLS size distribution and ζ-potential of PLGA NPs synthesized by mixing PVA and amino-
PVA with WOW synthesis. 
 
 
To demonstrate the suitability of the developed NPs for the release of hydrophilic drugs, FITC and 
fib-647 were encapsulated as model molecules. To note, the presence of FITC did not change 
substantially NPs features in terms of size distribution and polydispersity, as can be seen by 
comparing samples 10C and 10D with samples 10A and 10B, respectively. On the contrary, when 
fib-647 was encapsulated, larger NPs were obtained. This could be related to the higher MW of 
fib-647 if compared with the FITC molecule. In any case, sample 10E showed to be monodisperse 
and with an acceptable ζ-potential value. 
 
96 
 
3.2.2 Encapsulation of both hydrophilic and hydrophobic molecules: curcumin and fib-647 
 
WOW synthesis was employed also for the development of a system carrying molecules for 
multiple drug release, namely fib-647 and curcumin. A-fib-cur was found to have size (z-average 
294.3 nm) comparable to that of A-ctr and A-FITC (sample 10C and 10D, respectively). 
Monodispersity was very good (pdI 0.061), however a ζ-potential of +33.1 mV was found, thus 
indicating that curcumin influenced the amino-PVA arrangement on NPs surface. 
 
3.3 Degradation studies 
 
Further studies were performed on WOW samples because they represented the most appealing 
systems for the delivery of hydrophilic drugs. To assess PLGA NPs stability, the formulation 
obtained by WOW method with the surfactant mix PVA 0.975/amino-PVA 0.025% was selected 
(sample 10D). The sample 10C was studied as a control. Degradation was performed in PBS, at 
37°C, under mild rotation. In these conditions PLGA NPs were found to be stable for at least ten 
days (Fig. 32). Even if the derived count rate decreased of around 80% in 48 hours, the size 
distribution of PLGA NPs was maintained, as well as their polydispersity and peak shape.  
 
Fig. 32. Degradation profiles for amino-PVA stabilized PLGA NPs. The DLS measurements of 
WOW formulations with (sample 10D) or without (sample 10C) FITC - obtained with PVA 0.975% 
and amino-PVA 0.025%- were run over a period of 240 h. 
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4. Calcium Stearate as an effective alternative to PVA in PLGA nanoparticles 
synthesis 
 
4.1 Single emulsion synthesis. Optimization of calcium stearate-stabilized PLGA 
nanoparticles. 
 
PVA has been the favorite emulsifier in the synthesis of PLGA NPs because of its ability to form 
stable and uniformly distributed NPs97,108,110–112. Although amino-PVA was found to be effective in 
providing NPs with a positive charge, the amino-PVA stabilized NPs were still synthesized by 
means of 0.975% w/v PVA. Disadvantages in the use of this surfactant may be related to a partial 
evidence of toxicity and on the high amount of residual PVA that reduced NPs uptake 
capability115. Moreover, PVA is expensive and its employment influences the overall NPs cost.  
Calcium stearate (CSt) is a low cost thermal stabilizer already present in innovative medical 
devices. Its capability to act as a surfactant in PLGA NPs synthesis has not been explored so far. In 
this dissertation, it was hypothesized that CSt hydrophilic heads can be exposed towards the 
aqueous environment, while the polar tails embedding in the PLGA matrix. Accordingly, the 
stabilizing effect of CSt on NPs synthesis has been thoroughly investigated. Notably, investigation 
on the single parameter influences on PLGA NPs synthesis has been firstly performed on OW 
synthesis. Being this emulsion method simpler than the double emulsion one, it allowed to assess 
in an easier way variations induced by each single parameter. 
Preliminary synthesis gave evidence of CSt stabilizing effect that guarantees PLGA NPs formation. 
In fact, by adding CSt 20.0 mg/mL in the organic phase it was possible to obtain NPs with size 
205.3 nm (z-average) and a good pdI (0.055) after solvent evaporation. However, this procedure 
was not suitable for PLGA NPs synthesis, because NPs pellet after centrifugation was impossible to 
recollect. Apparently, CSt hydrophilic heads did not prevent NPs from sticking one to each other 
during the purification process. In order to improve NPs stability, an additional couple of 
surfactants, namely Polysorbate 60 (P60) and Span 60® (S60), were added.  
Sorbitan esters (Span®) and polyethoxylated sorbitan esters (Tween® or polysorbate) are two 
families of mild nonionic surfactants, having long-standing food and pharmaceutical approval, 
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thanks to their safe history of use. By using combination of Spans with their corresponding 
Tweens it is possible to prepare a variety of oil-in-water and water-in-oil emulsion systems. In 
fact, these surfactants present different characteristics in terms of hydrophobicity: polysorbates 
are hydrophilic while sorbitan esters show high hydrophobicity. Here, P60 and S60 were selected 
because part of their structure is in common with CSt, namely the stearic tail of the ester (Fig. 33). 
 
 
Fig. 33. Chemical structures of Polysorbate 60, P60 (panel A), and Span 60®, S60 (panel B). Red 
circles evidence the stearic portion of both molecules. 
 
4.1.1 Effect of P60-S60 ratio 
 
First, the P60-S60 optimal ratio was determined. In this regards, the S60 concentration was kept 
constant at 2.0 mg/mL while increasing the P60 concentration from 2.0 up to 5.0 mg/mL (Table 
11). Accordingly, the P60 amount was lower (sample 11B), equal (sample 11C) or higher (sample 
11D) than the S60 amount. In all cases, the PLGA NPs size was reduced and ζ-potential increased 
(resulted less negative) with respect to the synthesis with only CSt (sample 11A).  
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 S60  
(mg/mL) 
P60  
(mg/mL) 
 z-average  
(nm) 
Peak  
(nm) 
pdI ζ-potential 
(mV) 
11A 0 0  295.9 323.0 0.120 -52.0 
11B 2.0 2.0 P60<S60 207.3 221.4 0.091 NA 
11C 2.0 3.2 P60=S60 242.4 254.4 0.043 NA 
11D 2.0 5.0 P60>S60 205.3 216.8 0.055 -25.5 
Table 11. PLGA NPs formulations using the P60-S60 couple at different molar ratios. NA, not 
available 
 
 
 
Even if NPs obtained using S60 and P60 at the same molar ratio (sample 11C) showed a size 
slightly higher than the others two formulations (samples 11B and 11D), the pdI was the lowest 
and the NPs pellet after centrifugation was resuspended very easily. Therefore, the stoichiometric 
ratio between S60 and P60 was used in all the following experiments. 
In order to minimize the quantity of additional surfactants in PLGA NPs synthesis, a progressive 
reduction of S60 and P60 concentration was tested. As can be seen in Table 12, PLGA NPs size 
reduced when S60-P60 quantities were increased, whereas no clear trend was observed by 
progressively reducing the S60-P60 amounts. Interestingly, the use of S60 and P60 at 
concentration lower than 1.0 mg/mL and 1.6 mg/mL, respectively (samples 12D, 12E, 12F, 12G), 
resulted in polydisperse NPs that were very hardly resuspended after centrifugation. Moreover, 
the DLS analysis of the tested samples 12E and 12F showed more than one peaks, indicating NPs 
aggregation.  
For OW synthesis, S60 1.0 mg/mL and P60 1.6 mg/mL were selected as the best concentrations to 
employ, being the lowest possible that guaranteed NPs with acceptable size and monodispersity.  
100 
 
 
 
 
 S60 (mg/mL) P60 (mg/mL) z-average (nm) Peak (nm) pdI 
12A  3.0 4.8 228.5 246.1 0.090 
12B  2.0 3.2 242.4 254.4 0.043 
12C  1.0 1.6 253.9 271.0 0.081 
12D  0.75 1.2 343.5 312.6 0.307 
12E  0.5 0.8 318.0 239.8+708.5 0.268 
12F  0.4 0.6 310.4 237.7+837.8 0.393 
12G  0.25 0.4 271.5 244.2 0.288 
Table 12. PLGA NPs formulations using the P60-S60 couple at different concentrations. For all of 
these syntheses, CSt concentration was kept constant at 20.0 mg/mL. 
 
 
 
 
4.1.2 Effect of calcium stearate concentration 
 
After having optimized the P60-S60 ratio in the PLGA NPs synthesis, the CSt role as stabilizer was 
thoroughly investigated (Table 13). When no CSt was added (sample 13A), samples presented 
multiple peaks and polydispersity higher than all the other samples. Interestingly, by increasing 
the CSt concentration from 5.0 to 40.0 mg/mL (samples from 13B to 13F) the NPs size was found 
to be reduced up to about 290 nm. However, differences were not indicative.  
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 CSt (mg/mL) z-average (nm) Peak (nm) pdI Degradation (days) 
13A 0 494.8 521.9+5213 0.396 - 
13B  5.0 322.5 348.0 0.133 <1 day 
13C 10.0 309.9 336.9 0.098 8 
13D 20.0 309.7 325.3 0.146 3 
13E 30.0 307.0 318.8 0.177 3 
13F 40.0 288.2 307.7 0.139 <1 
Table 13. PLGA NPs formulations using CSt at different concentrations. For all of these syntheses, 
P60 and S60 concentrations were kept constant at 1.6 and 1.0 mg/mL, respectively. 
 
Preliminary studies on NPs degradation indicated that PLGA NPs synthesized with CSt 10.0 mg/mL 
were stable up to eight days in physiological mimicking conditions, while for all the other tested 
concentrations NPs degraded in less than three days. Apparently, too high concentration of CSt 
weakens PLGA structure and can interfere with the overall NPs arrangement. On the contrary, low 
CSt quantity was not sufficient to guarantee NPs resistance during time. Consequently, CSt 10.0 
mg/mL was used in all the following experiments.  
 
4.1.3 Encapsulation of hydrophobic molecule: curcumin 
 
PLGA NPs encapsulating curcumin were synthesized and the best curcumin quantity was 
evaluated. As can be seen from Table 14, curcumin has a role in stabilizing NPs size and size 
distribution. In fact, when the lowest amount of curcumin was added (2.5 mg/mL, sample 14B), 
NPs showed a sharp increase in diameter and polydispersity. Similar results were observed using 
curcumin at the concentration of 10.0 mg/mL (sample 14D). In this case, the presence of 
aggregates was also detected. Differently, when curcumin was added the tenth with respect to 
the PLGA polymer (sample 14C), NPs with size comparable to the corresponding sample without 
encapsulated drug (sample 13C) were obtained. This is in accordance to previous findings in the 
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literature129–131. Consequently, 5.0 mg/mL was selected as optimal drug concentration in the PLGA 
NPs synthesis. 
 
 Curcumin (mg/mL) z-average (nm) Peak (nm) pdI 
14A 0 306.6 327.3 0.127 
14B 2.5 408.2 438.6 0.219 
14C 5.0 300.2 313.4 0.151 
14D 10.0 383.1 386.0+5349 0.343 
Table 14. PLGA NPs formulations using curcumin at different concentrations. 
 
Actual encapsulation of the drug in sample 14C was assessed by confocal microscopy. As shown in 
Fig. 34, colocalization was found between fluorescence signal of curcumin and NPs contrast phase 
image.  
 
 
Fig. 34. Confocal characterization of C-OW-cur (panel A, B, C) and its control C-OW-ctr (panel D, 
E, F). Fluorescence detected in panel A was found to colocalized (panel C) with contrast phase 
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image (panel B). This was not the case for the control sample (panel D fluorescence channel, 
panel E contrast phase, panel F merge). Scale bar is 5 µm. 
 
The encapsulation of curcumin into the PLGA NPs (sample 14C) was further investigated by 
stimulated emission depletion (STED) microscopy, that is characterized by better resolution with 
respect to confocal microscopy and has shown to be a useful tool in detecting nano-sized 
systems132. Considering the STED image (Fig. 35), two main points can be raised. The NPs spots 
were less bright than in confocal microscopy images, as expected due to the high power of the 
laser that resulted in partial fluorophore bleaching. Conversely, STED provided a higher resolution 
and the homogeneous distribution of curcumin within the NPs was observed.  
 
 
Fig. 35. STED microscopy image of curcumin loaded CSt stabilized PLGA NPs. The scale bar is 1 
µm. 
 
4.2 Double emulsion synthesis. Parameter investigation 
 
Similarly to OW synthesis, a systematic analysis was also performed on WOW synthesis. In 
particular, attention was focused on the surfactants concentration.  
Table 15 reported the size and ζ-potential of PLGA NPs synthesized by WOW method. The CSt 
concentration was fixed at 10.0 mg/mL, whereas the concentration of S60 and P60 was increased 
while keeping constant their ratio. As in the case of OW synthesis, the P60-S60 surfactants couple 
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was necessary for reducing NPs size and polydispersity (compare sample 15A vs. other samples). 
When increasing the amount of P60 and S60, NPs size decreased. However, by increasing P60-S60 
concentrations from 2.0-3.2 mg/mL to 3.0-4.8 mg/mL only a 10-nm reduction in NPs size was 
observed (sample 15C vs. sample 15D).  
Notably, the increase of S60 and P60 concentrations from 1.0-1.6 mg/ml to 2.0-3.2 mg/mL 
allowed to considerably reduce the NPs size (from 293.9 to 250.9 nm) and improve the NPs 
stability (ζ-potential was more negative, from -21.7 to -25.5 mV). Therefore, formulation 15C was 
additionally investigated.   
 
 
 S60  
(mg/mL) 
P60  
(mg/mL) 
z-average  
(nm) 
Peak  
(nm) 
pdI ζ-potential  
(mV) 
15A  0 0 409.6 394.9+1971 0.235 -19.6 
15B 1.0 1.6 293.9 322.5 0.114 -21.7 
15C 2.0 3.2 250.9 270.9 0.074 -25.5 
15D 3.0 4.8 243.5 261.8 0.108 -28.9 
Table 15. PLGA NPs formulations using P60 and S60 at different concentrations in WOW 
synthesis. For all of these syntheses, CSt concentration was kept constant at 10.0 mg/mL. 
 
 
In WOW synthesis, the role of CSt was found to be similar as in OW synthesis (Table 16), being the 
CSt able to reduce NPs size (samples 16A vs. other samples). As a control, NPs were synthesized 
without CSt and with P60-S60 at the concentration of 1.6-1.0 mg/mL respectively. The obtained 
NPs were smaller (z-average 469.7 nm, main peak 468.5 nm) than the corresponding ones 
obtained by OW synthesis (sample 13A), as expected because ultrasounds were applied twice. No 
main differences were found by adding 10.0, 20.0 or 30.0 mg/mL of CSt in terms of size, 
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polydispersity and ζ-potential, therefore 10.0 mg/mL CSt was maintained as the optimal amount 
in all the following syntheses.  
 
 CSt (mg/mL) z-average (nm) Peak (nm) pdI ζ-potential (mV) 
16A  0 303.1 323.5 0.065 -32.6 
16B 10.0 250.9 270.9 0.074 -25.5 
16C  20.0 266.4 283.8 0.127 -24.6 
16D  30.0 256.7 274.6 0.092 -22.9 
Table 16. PLGA NPs formulations using CSt at different concentrations. For all of these syntheses, 
P60 and S60 concentrations were kept constant at 3.2 and 2.0 mg/mL, respectively. 
 
 
 
4.2.1 Encapsulation of hydrophilic molecules: fib-647, FITC 
 
In the case of WOW synthesis, fibrinogen-labeled with Alexa 647® (fib-647) (C-fib) was selected as 
hydrophilic model molecule. C-fib showed higher size (z-average 282.7 nm) than the 
corresponding control without adding fib-647 (sample 16B, z-average 250.9 nm). Both the 
samples presented very good monodispersity, with a pdI less than 0.09. This suggested that fib-
647 was effectively encapsulated in CSt stabilized PLGA NPs.  
Further evidence of the actual fib-647 encapsulation was provided by confocal characterization 
(Fig. 36). 
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Fig. 36. Confocal characterization of C-fib (panel A, B, C) and its control C-ctr (panel D, E, 
F).Fluorescence detected in panel A was found to colocalized (panel C) with contrast phase image 
(panel B). This was not the case for the control sample (panel D fluorescence channel, panel E 
contrast phase, panel F merge). Scale bar is 5 µm. 
 
In addition, FITC was selected as hydrophilic molecule with low MW and encapsulated during the 
WOW synthesis. Notably, C-FITC size (z-average 311.8 nm) was higher than C-fib. Apparently, the 
proteic nature of fibrinogen acted as an additional stabilizer for the double emulsion that resulted 
in lower particles.  
 
4.2.2 Encapsulation of both hydrophilic and hydrophobic molecules: curcumin and fib-647 
 
In addition, a system encapsulating both curcumin and fib-647 was explored (C-fib-cur) as 
multiple drug release system. Controls experiments were performed to investigate the influence 
of either curcumin or fib-647 in determining the overall NPs feature. In particular, NPs were 
synthesized by WOW encapsulating either curcumin in the polymeric shell (C-cur) or fib-647 in the 
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aqueous inner core (C-fib, see 4.2.1 Encapsulation of hydrophilic molecules: fib-647, FITC page 
105 in the Results and discussion section).  
C-fib-cur showed higher size (z-average 292.1 nm) and polydispersity (pdI 0.207) than the 
corresponding core-shell NPs without curcumin (C-fib). This was expected because of the addition 
of curcumin in the NPs formulation. Differently, C-fib-cur showed size comparable to that 
determined for C-cur (z-average 297.4 nm); therefore, these data did not provide clear indication 
on the effective fib-647 encapsulation.  
However, the confocal microscopy analysis (Fig. 37) allowed to evidence that both fib-647 and 
curcumin were simultaneously incorporated in the CSt stabilized PLGA NPs.  
 
 
Fig. 37. Confocal characterization of C-fib-cur. Fluorescence was detected for both curcumin 
(panel A) and fib-647 (panel C) fluorescence channel. To note, the fluorescent spots co-localized 
between them and the contrast phase (panel B) image (circles). Scale bar is 5 µm. 
 
 
4.3 Morphology study. SEM 
 
To complete the NPs morphological characterization, SEM analyses was performed. As can be 
seen in Fig. 38, NPs was round shape and with a narrow polydispersity.  
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Fig. 38. Scanning Electron Microscopy characterization of C-OW-cur. CSt stabilized NPs were 
found to be round shape and monodisperse. Scale bar is 5µm. 
 
 
 
 
4.4 Degradation study 
 
The degradation study of CSt stabilized PLGA NPs was performed on the samples reported in 
Table 17. For comparison purpose, all the syntheses (included the OW ones) were run with CSt 
10.0 mg/mL and S60-P60 2.0-3.2 mg/mL. Curcumin was encapsulated as hydrophobic drug in 
PLGA NPs obtained by both OW (C-OW-cur) and WOW (C-cur) syntheses, while in the aqueous 
core of core-shell NPs the fib-647 was encapsulated (C-fib). For multiple drug release purpose, 
PLGA NPs containing both the drugs (C-fib-cur) was investigated. Controls samples for both OW 
(C-OW-ctr) and WOW (C-ctr) without model molecules were additionally considered. Noteworthy, 
DLS data reported in Table 17 referred to the means of four different replicates and showed very 
good reproducibility in terms of both size and size distribution.  
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 z-average (nm) pdI 
C-OW-ctr 293.1 ± 29.7 0.157 ± 0.071 
C-OW-cur 326.1 ± 32.6 0.210 ± 0.045 
C-ctr 256.8 ± 15.6 0.083 ± 0.008 
C-cur 296.8 ± 28.2 0.208 ± 0.033 
C-fib 280.8 ± 13.9 0.118 ± 0.034 
C-fib-cur 295.8 ± 8.7 0.206 ± 0.031 
Table 17. DLS characterization of CSt stabilized NPs synthesized by OW and WOW methods. DLS 
data are expressed as mean ± standard deviation (n = 4). 
 
When performing degradation study, it was found that curcumin reduced the PLGA NPs stability. 
In fact, C-OW-cur, C-cur and C-fib-cur showed a rapid decrease in count rate and were found to be 
completely degraded in about nine days. On the other hand, samples without curcumin (C-OW-
ctr, C-ctr, C-fib) had constant DCR values until day 4. Then the number of detected photons 
showed a sharp drop, and finally the DCR decreased slowly until complete degradation, that 
occurred at day 28 (Fig. 39, panel A). 
 
 
Fig. 39. Degradation studies on CSt PLGA NPs. Panel A reported Derived Count Rate trend, while 
Panel B referred to peaks size percentage values during time. 
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Evidently, it was found that the degradation process followed different mechanisms in the 
presence or absence of curcumin. This was even more clear considering the NPs size (Fig. 39, 
panel B). In fact, in samples C-OW-ctr, C-ctr and C-fib NPs size was found to be stable during time. 
On the other hand, for samples encapsulating curcumin, trends were different but in all cases the 
NPs peak size increased before complete degradation. This behavior is compatible with a release 
of the drug followed by the NPs matrix swelling. To note, this behavior was accentuated for C-
OW-cur, for which it is possible to hypothesize that a higher amount of drug was encapsulated.  
 
 
 
 
 
 
4.5 Release study 
 
By taking advantage of the optical properties of the selected model molecules, namely curcumin 
and fib-647, release studies by the dissolution technique136 were performed using 
spectrofluorimetry. Quantification was possible thanks to the calibration curves presented in the 
Materials and methods section, paragraph 7.1 Calibration curve for curcumin page 63 and 7.2 
Calibration curve for fib-647 page 64. 
For NPs encapsulating curcumin, a clear trend was found (Fig. 40, panel A). The most majority of 
the drug was released after 24 h of incubation, but the release was sustained up to day 15, 
especially for C-OW-cur. Surprisingly, C-cur showed a higher release with respect to C-fib-cur. 
Apparently, the simultaneous presence of both molecules interfered with the curcumin release.  
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Fig. 40. Cumulative release of curcumin (panel A) and fib (panel B) as assessed by 
spectrofluorometer. 
 
Unfortunately, the quantification of fib-647 was not possible because of technical issues in 
assessing the content of encapsulated drug. Accordingly, only a cumulative release as assessed by 
the relative percentage of collected photon was provided. As can be seen in Fig. 40 (panel B), also 
in the case of fib-647 a fast release was observed in the first 24 h, followed by a sustained release 
during the following 15 days for both C-fib and C-fib-cur.  
 
 
 
 
5. D-Mannose and protein corona decorations 
 
5.1 DLS characterization 
 
After having optimized experimental parameters in the synthesis of either amino-PVA or CSt 
stabilized PLGA NPs, further surface functionalization was investigated for specific TAMs 
targeting. To this aim, mannose was selected to decorate NPs surface because of the 
overexpression of the mannose receptor CD206 on TAMs external membrane. 
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Although a variety of surface functionalization strategies have been developed to provide NPs 
with specific targeting, recognition properties of these systems are poorly evident in vitro146. This 
is mainly due to serum-proteins interactions with the NPs, which could highly affect their fate. 
Indeed, proteins can physically cover active targeting moieties on the NPs surface or interfere 
with their specific functions, thus the biological outcomes of NPs can be significantly altered with 
respect to predicted activity. 
In this dissertation, it was hypothesized that the interactions between serum proteins and NPs 
surface can be exploited as a strategy to prevent the inactivation of NPs targeting moieties.  
More specifically, PLGA NPs were incubated in a mixture consisting of 10.0% v/v FBS and 20.0% 
w/v D-mannose (FBSM). For comparison, also different conditions were tested, namely 10.0% v/v 
FBS without mannose (FBS), 100% FBS with (100FBSM) and without (100FBS) 20.0% w/v 
mannose. DLS analyses for size and ζ-potential were performed to evaluate the formation of the 
NPs protein corona and its effect on the NPs surface properties.  
Samples selected for this experimental set included C-fib and C-fib-cur, as well as A-OW-ctr, A-ctr, 
A-fib and A-fib-cur.  
As can be seen in Table 18, in all tested samples the addition of D-mannose in the incubating 
mixture led to an increase in size (FBSM vs. FBS and 100FBSM vs. 100FBS), with the exception of 
C-fib. This can be referred to the actual adsorption of D-mannose on NPs surface.  
Notably, for CSt stabilized PLGA NPs the increase in size was also dependent on the protein 
amount, having samples incubated with 100FBS a higher size than those incubated with FBS. 
Differently the amino-PVA stabilized NPsdid not change their diameters after incubation with 
100FBS but increased up to 138% (A-fib) after incubation with FBS.  
Finally, A-ctr did not show substantial variation in size in all the incubation conditions, suggesting 
that this sample had more stealth properties than the other ones.  
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Sample FBSM FBS 100FBSM 100FBS 
C-fib 125.9% 150.7% 253.9% 239.2% 
C-fib-cur 148.7% 109.9% 238.2% 188.9% 
A-OW-ctr 164.7% 125.2% 194.6% 99.3% 
A-ctr 97.0% 93.3% 97.4% 83.5% 
A-fib 169.7% 138.4% 162.0% 96.5% 
A-fib-cur 184.5% 130.6% 133.8% 96.7% 
Table 18. Percentage of increase in PLGA NPs size after incubation with different media (FBSM, 
FBS, 100FBSM, 100FBS). 
 
 
 
Of particular interest were the ζ-potential analyses (Table 19). C-fib did not showed differences in 
the surface charge values before and after incubation with FBS, at all the tested conditions. In a 
different way, the FBS concentration affected the overall surface charge of C-fib-cur sample, being 
ζ-potential more negative using 100FBSM and 100FBS. Considering the amino-PVA stabilized NPs, 
the positive ζ-potential measured at time 0 became negative for all the incubation conditions. 
Apparently the cationic surface of the NPs attracted anionic proteins that converted their surface 
charge, even if NPs size was not substantially affected as in the case of A-ctr. To note, in both CSt 
and amino-PVA stabilized NPs, D-mannose addition did not substantially change the NPs surface 
charge, as expected being this molecule without net charge (see chemical structure in Fig.10). 
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Sample Time 0 FBSM FBS 100FBSM 100FBS 
C-fib -26.9 -25.8 -28.4 -25.1 -24.0 
C-fib-cur -24.9 -25.0 -24.8 -32.2 -37.2 
A-OW-ctr +23.6 -22.4 -24.0 -18.7 -22.8 
A-ctr +36.2 -25.6 -26.5 -20.6 -20.0 
A-fib +24.3 -23.5 -23.7 -24.6 -19.9 
A-fib-cur +24.3 -22.4 -23.4 -22.8 -15.4 
Table 19. ζ-potential (mV) values after incubation with FBS, FBSM, 100FBS and 100FBSM. 
 
 
5.2 XPS characterization 
 
An additional analysis with X-ray photoemission spectroscopy (XPS) was performed on a 
representative sample (A-ctr). In particular, this technique was selected to understand if D-
mannose was effectively adsorbed on the NPs surface. To avoid any interference during analysis 
from proteins component, A-ctr was incubated with 20.0% w/v D-mannose without FBS and 
carbonium profiles before and after incubation are reported in Fig. 41. In sample treated with D-
mannose, NPs surface presented an increased percentage of -C-OH bond. This leaded to a 
different response in XPS analysis. 
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Fig. 41. XPS analysis of NPs after incubation with 20.0% w/v D-mannose. 
 
 
 
6. Cytotoxicity studies 
 
The cytocompatibility of the PLGA NPs was assessed by MTT test. Particular focus was done on 
either CSt or amino-PVAstabilized PLGA NPs encapsulating the hydrophilic model molecule FITC. 
Accordingly, C-FITC and A-FITC were synthesized by WOW method in sterile conditions, as well as 
their respective controls without FITC, C-ctr and A-ctr. To evaluate the effect on cytocompatibility 
of the NPs components as well as the surface decoration for specific TAMs targeting, different 
conditions were selected. In particular, each sample underwent 24 h incubation in 20% w/v D-
mannose (M), or 10% v/v FBS (FBS),or 10% v/v FBS and 20% w/v D-mannose (FBSM). Moreover, 
non treated NPs were used at two different dilutions, namely 1 to 100 (C-FITC, C-ctr, A-FITC, A-ctr) 
and 1 to 10 (C-FITC 2, C-ctr 2, A-FITC 2, A-ctr 2) in PBS 1X. 
In RAW264.7 culture, CSt stabilized NPs (C-FITC and C-ctr) showed very good cytocompatibility 
(Fig. 42). Cell viability was higher than 90% for all the tested conditions and no differences were 
found even at high NPs concentration (C-FITC 2 and C-ctr 2). Surface modification by adsorption of 
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D-mannose or proteins was found to be as safe as unmodified NPs. Apparently, slightly reduction 
in cell viability had to be ascribed to the NPs components rather than their surface 
functionalization. To note, the experimental reliability was confirmed by both positive and 
negative controls.  
 
 
 
Fig. 42. MTT of CSt PLGA NPs on RAW264.7 culture. MTT test of CSt stabilized PLGA NPs 
synthesized by WOW. Two formulations were tested, namely with (C-FITC) or without (C-ctr) FITC. 
Each sample tested after different incubation conditions (M: 20.0% w/v D-mannose; FBS: 10.0% 
v/v FBS; FBSM: 10.0% v/v FBS and 20.0% w/v D-mannose; 2: dilution 1 to 10 in PBS 1X). Untreated 
(UT) and PBS treated samples were used as negative controls, while ethanol (EtOH) and DMSO 
were the positive controls, being cytotoxic agents. NPs were diluted 1 to 100 before 24 
hincubation with cells. 
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The viability ofRAW264.7 after 24 h incubation with amino-PVA stabilized NPs (A-FITC and A-ctr) 
ranged from 62.2 to 79.8% (Fig. 43). Cytocompatibility was found to be lower than that observed 
for CSt stabilized samples, as expected because of the presence of cationic charge on the NPs 
surface. Notably, bioavailabilityin this case was dependent on the surface decoration, being cells 
treated with non-decorated NPs more viable than all the other conditions.  
 
 
 
Fig. 43. MTT of amino-PVA PLGA NPs on RAW264.7 culture. MTT test of amino-PVA stabilized 
PLGA NPs synthesized by WOW. Two formulations were tested, namely with (A-FITC) or without 
(A-ctr) FITC. Each sample tested after different incubation conditions (M: 20.0% w/v D-mannose; 
FBS: 10.0% v/v FBS; FBSM: 10.0% v/v FBS and 20.0% w/v D-mannose; 2: dilution 1 to 10 in PBS 
1X). Untreated (UT) and PBS treated samples were used as negative controls, while ethanol 
(EtOH) and DMSO were the positive controls, being cytotoxic agents. NPs were diluted 1 to 100 
before 24 h incubation with cells. 
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Cytotoxicity studies were performed also on a primary culture of mouse bone marrow-derived 
macrophages. These cells are more sensitive than commercially available cell lines such as 
RAW264.7, thus representing a model that better mimic in vivo conditions. Cytocompatibility of 
CSt stabilized NPs were found to be lower than in the case of RAW264.7 cell line, as expected 
because of the higher cells susceptibility (Fig. 44). Moreover, higher error bars as well as reduced 
effect of cytotoxic agents (EtOH and DMSO) indicated an increased variability in the cellular 
response. However, cells viability was always higher than 83%, thus indicating good 
cytocompatibility for CSt stabilized NPs. No major differences were observed between unmodified 
NPs and NPs decorated under different conditions. 
 
 
 
Fig. 44. MTT of CSt PLGA NPs on primary culture of mouse bone marrow-derived macrophages. 
MTT test of CSt stabilized PLGA NPs synthesized by WOW. Two formulations were tested, namely 
with (A-FITC) or without (A-ctr) FITC. Each sample tested after different incubation conditions (M: 
20.0% w/v D-mannose; FBS: 10.0% v/v FBS; FBSM: 10.0% v/v FBS and 20.0% w/v D-mannose; 2: 
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dilution 1 to 10 in PBS 1X). Untreated (UT) and PBS treated samples were used as negative 
controls, while ethanol (EtOH) and DMSO were the positive controls, being cytotoxic agents. NPs 
were diluted 1 to 100 before 24 h incubation with cells. 
 
Finally, amino-PVA stabilized NPs were incubated with primary culture of mouse bone marrow-
derived macrophages. As can be seen inFig.45, a high variability was observed especially for A-
FITC. For this sample, surface decorated NPs at all the tested conditions were found to be less 
cytotoxic than the unmodified sample. This was in accordance with data previously reported for 
RAW267.4 cells. A-ctr showed similar biocompatibility for all the tested conditions (cells viability 
ranged from 73.4 to 77.6%). 
 
 
Fig.45. MTT of amino-PVA PLGA NPs on primary culture of mouse bone marrow-derived 
macrophages. MTT test of amino-PVA stabilized PLGA NPs synthesized by WOW. Two 
formulations were tested, namely with (A-FITC) or without (A-ctr) FITC. Each sample tested after 
different incubation conditions (M: 20.0% w/v D-mannose; FBS: 10.0% v/v FBS; FBSM: 10.0% v/v 
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FBS and 20.0% w/v D-mannose; 2: dilution 1 to 10 in PBS 1X). Untreated (UT) and PBS treated 
samples were used as negative controls, while ethanol (EtOH) and DMSO were the positive 
controls, being cytotoxic agents. NPs were diluted 1 to 100 before 24 h incubation with cells. 
 
To note that no major differences were observed between FITC encapsulating systemsand their 
controls.  
These results indicated that the developed PLGA NPs, especially those CSt stabilized, were 
effectively biocompatible. Further experiments are necessary to confirm NPs biocompatibility 
even at longer exposition time.   
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Conclusions 
 
This dissertation was related on the development of polymeric NPs for the specific targeting of 
Tumor Associated Macrophages (TAMs) as an innovative therapeutic approach for cancer 
treatment.  
Poly (Lactic-co-Glycolic) Acid (PLGA) as safe and versatile material has been used for the 
development of NPs by single (OW) or double (WOW) emulsion-solvent evaporation method. 
Different synthetic parameters have been thoroughly investigated, with particular focus on the 
surfactant role.  
The well studied Poly Vinyl Alcohol (PVA) was employed to study the PLGA behavior in both OW 
and WOW synthesis. Many parameters, including polymer MW and concentration, nature of 
organic solvent, primary aqueous phase content, ultrasound application, cooling bath 
temperature and surfactant properties in terms of MW and concentration, have been thoroughly 
investigated. PVA stabilized NPs underwent also a careful analysis of their degradation properties, 
with the employment of innovative techniques based on single particle optical extinction and 
scattering (SPES).  
Chemical modification of the PVA structure led to the synthesis of a new polymer, amino-PVA, 
which has been characterized before its employment as surfactant in PLGA NPs synthesis. The 
cationic charge presented by amino-PVA is supposedto modulate NPs ability to enter the cells and 
specially to escape the endosome. Amino-PVA stabilized PLGA NPs synthesis has been optimized 
and their degradation properties investigated. 
Moreover, calcium stearate (CSt) has been presented asan alternative surfactant able to 
guarantee NPs stability, size and polydispersity similar to PVA, while improving biocompatibility, 
safety and cost-effectiveness. Parameters involved in CSt stabilized NPs synthesis were thoroughly 
studied as well as degradation and drug release properties of the developed NPs.  
Both amino-PVA and CSt stabilized NPs were found to be able to load curcumin and 
biomacromolecules, either alone or in combination. Accordingly, the most suitable formulation 
for drug and gene delivery underwent further investigations. 
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In order to improve NPs biocompatibility and specific TAMs targeting for both amino-PVA and CSt 
PLGA NPs, strategies for surface decoration have been investigated. D-mannose as specific 
molecules to guarantee macrophages recognition was added on the NPs surface in combination 
with a protein mixture, as a strategy to prevent the inactivation of NPs targeting moieties due the 
protein corona formation on NPs surface.  
Finally, cytocompatibility of the amino-PVA and CSt stabilized NPs have been assessed. All the 
tested formulations were found to be cytocompatibile for at least 24 h incubation. Further 
evaluations of their biocompatibility for longer time exposition have to be performed, as well as a 
careful evaluation of the NPs fate inside the cells after internalization.   
 
 
 
This work was possible thanks to the “Fondo per gli Investimenti della Ricerca di Base” 
(Inflammation and cancer: nanotechnology-based innovative approaches, protocol 
RBAP11H2R9, year 2010).  
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Appendix 1 
 
Embedded poly(lactide-co-glycolide) nanoparticles in a micro-pattern collagen 
scaffold enhanced neuronal tissue regeneration 
Limitation in using ethyl acetate as organic solvent was found when monoclonal anti-human CD4-
FITC conjugate (CD4-FITC) was encapsulated as model molecule in the NPs inner core (P-CD4-
FITC). In this case, NPs synthesized by means of ethyl acetate showed good size (z-average 245.0 
nm) and a pdI below 0.15. However too many naked-eye visible aggregates formed during NPs 
synthesis, leading to a reduction in the final NPs yield. This was probably due to the non ideal 
condition in the antibody dispersing medium that affected NPs formation. In fact, it was 
previously reported by Tu F. and Lee D. that the stability of PLGA double emulsions systems 
depends on the content and the pH of the inner aqueous phase147.  
On the contrary, synthesis by means of DCM and 4.0% w/v PVA (P4-CD4-FITC) were more 
efficient, even if NPs were slightly bigger (z-average 319.0 nm, pdI 0.199).  
These PLGA NPs were tested as candidates for the implementation of collagen-based scaffolds. 
Thanks to the collaboration with Dr. Laura Blasi (NNL Institute of Nanoscience CNR Lecce, Italy), it 
was investigated whether collagen-based scaffolds with axially oriented pores, with a pore size 
suitable for nerve regeneration, can be implemented with PLGA NPs for the sustained and 
localized release of neurocytokines in the regeneration of long nerve gaps. In the collaborative 
project, collagen-based scaffolds were synthesized by means of freeze-drying and carbodiimide-
based crosslinking. PLGA NPs with a fluorescent antibody were embedded in the scaffold matrix 
during the freeze drying process. CD4-FITC was selected as encapsulated model molecule to (i) 
monitor the particles location within the scaffold; (ii) measure the release kinetics of the 
encapsulated molecule from the scaffold; (iii) verify the molecule’s bioactivity in cell culture 
experiments.  
With the aim to prolong PLGA NPs stability during time and allow sustained neurocytokines 
release, a different monomer ratio was tested: instead of an equal amount of lactic and glycolic 
monomer (50:50), Lactel® B6001-1P with 65:35 ratio was employed. In fact, lactic acid is more 
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hydrophobic than glycolic acid. PLGA copolymers containing higher amount of lactide monomer 
are consequently less hydrophilic, absorb less water, and degrade slower87. Moreover, to protect 
PLGA NPs during the freeze drying process necessary to the scaffold synthesis, D-mannitol was 
used as cryoprotectant.  
Reproducibility was very good: DLS analysis showed NPs with peak size of 328.6±18.4 nm and a 
pdI of 0.229±0.09 in five different replicates.  
The same procedure was used to encapsulate in PLGA NPs a different fluorophore, Cy™3 
AffiniPure Goat Anti-Mouse IgG (H+L) (IgG1-Cy3), in order to investigate the system versatility to 
encapsulate different molecules. P4-IgG-Cy3 NPs showed a 30 nm higher size peak (359.4 nm) 
with respect to P4-CD4-FITC and an acceptable pdI (0.216).  
Confocal microscope analyses were performed before embedded the PLGA NPs in the scaffold, in 
order to assess effective encapsulation of the model fluorophores. As can be seen in Fig. 46 
almost all the NPs showed a fluorescent spot due to the presence of CD4-FITC or IgG-Cy3 in the 
NPs inner core. 
 
Fig. 46. Confocal microscope analyses for P-CD4-FITC and P-Cy3. By merging (C, F) the phase 
contrast (B, E) and the fluorescent channels images (A, D), it was possible to note that almost all 
the NPs actually encapsulated either IgG-Cy3 or CD4-FITC. Scale bar is 5 µm. 
126 
 
Materials and methods  
 
Water-in-oil-in-water (WOW) samples encapsulating Cy™3 AffiniPure Goat Anti-Mouse IgG (H+L) 
(IgG-Cy3, Jackson Immuno) or monoclonal anti-human CD4-FITC conjugate (CD4-FITC, Sigma 
Aldrich, a kind gift of Dr. Laura Blasi, from NNL Institute of Nanoscience CNR - Lecce, Italy) were 
obtained by the use of PLGA 65:35, MW 40-75,000 (Lactel® B6001-1P, ester terminated).  
First, 15 µL of 0.1 mg/mL antibody were added at 300 µL of PLGA in dichloromethane (DCM). 
Primary water-in-oil emulsion was obtained by means of 15 sec ultrasounds at 30% of amplitude 
in ice bath. Then, 1.2 mL of 4.0%w/v Poly(Vinyl) Alcohol (PVA, Mowiol® 4-88 MW 31,000, 86.7-
88.7 mol% hydrolysis) were addition and sonicated using the same protocol described above, thus 
obtaining the multiple water-in-oil-in-water emulsion. Finally, the WOW emulsion was diluted in 
15 mL of dispersing phase (0.4% w/v PVA) and solvent was evaporated via magnetic stirring for 
3.5 h.  
P-Cy3 and P-CD4-FITC were collected and washed with three cycles of centrifugation at 15,000 g 
for 20 min at 4°C, in order to remove exciding surfactant, as well as not encapsulated antibodies. 
Pellets were then resuspended in 1.0 mL of 20% w/v D-mannitol and an additional centrifugation 
cycle was done before samples stocking.  
Samples characterization was performed as described in the paragraph 5. Nanoparticle 
characterization page 54 of the Materials and methods section of the main text.  
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Appendix 2 - The Nanotox project 
 
This work has been supported by Fondazione CARIPLO for the project “Toxicology of chronic 
exposure to engineered silver nanoparticles”, under the Program “Nanoparticles, 
nanotechnologies and ultrafine particles". 
 
 
1. A Practical Approach to Assess the Stability of Isolated Silver Nanoparticles in 
Complex Biological Media 
 
Abstract 
 
The widespread use of engineered silver nanoparticles (AgNPs) in commercial products is 
currently raising concerns about their potential for adverse health effects in humans and 
environment. Although an increasing number of studies in vitro and in vivo are being reported on 
the toxicity of AgNPs, most of them suffer from incomplete characterization of AgNPs in the 
tested biological media. Hence the issue of toxicity is an open critical question and the 
comparison of toxicological data very difficult. Accordingly, the development of a practical and 
reliable method for assessing correct size and attitude to reactivity of AgNPs under the exposure 
conditions is urgently required to predict the toxicological effects of AgNPs. 
Here we studied the stability of AgNPs in two relevant biological media, namely 10% Fetal Bovine 
Serum (FBS), which resembles the protein composition of a typical cell medium, and mouse 
plasma (MP). In this regard, three different techniques (Dynamic Light Scattering, Transmission 
Electron Microscopy, UV-vis spectroscopy) were tested for their suitability in detecting AgNPs of 
three different sizes (10, 40 and 100 nm) coated with either citrate or polyvinylpyrrolidone (PVP). 
Results showed that UV-vis spectroscopy was the most versatile technique to predict the behavior 
of such a wide range of AgNPs conditions, because of its ability to characterize all the tested 
AgNPs in both the examined biological media. Finally our discussion provides comprehensive 
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guidelines to interpret the UV-vis spectra and assess the AgNPs stability in practical experimental 
settings. 
 
Introduction 
 
Because of their enhanced antiseptic activity, engineered silver nanoparticles (AgNPs) – i.e. 
intentionally produced silver particles with size ranging from 1 to 100 nm- are currently 
incorporated in an increasing number of consumer products148–151. 
The widespread use of AgNPs and their subsequent disposal in the environment imply that human 
exposure to AgNPs is expected to increase in the future, therefore the assessment of AgNPs 
toxicity (in vitro and in vivo) is urgently needed to guarantee consumer safety152–154 
AgNPs can entry the body through different routes (ingestion, inhalation, dermal contact) and 
reach the systemic circulation155. It is widely established that AgNPs in biological media such as 
blood readily interact with surrounding biomolecules (proteins, lipids, etc), leading to the 
formation on their surface of a protein corona101,156. The protein coated AgNPs represent new 
molecular entities that determine the biological response, including cellular uptake, route of 
clearance and accumulation in target organs and tissues102. 
AgNPs in biological fluids can also lead to agglomeration (i.e. weakly bonded particles), 
aggregation (i.e. strongly bonded or fused particles) as well as release of silver ions, thus their size 
can be highly different from that reported by the manufacturer157–160. 
To date, an increasing number of studies on the toxicity of AgNPs have been reported100,161–163. 
However, many key questions on the AgNPs toxicity mechanism still remain unanswered. The 
main reason is the lack of proper characterization of the tested AgNPs under the exposure 
conditions, which makes difficult to attribute a certain property to the observed toxic effects. 
To this purpose, Murdock et al. exploited Dynamic Light Scattering (DLS) in conjunction with 
Transmission Electron Microscopy (TEM) to determine the physicochemical characteristics of a 
wide range of nanomaterials, including AgNPs, in complex biological media164. However, the 
detection of AgNPs with these techniques suffered from several drawbacks. Interpreting the DLS 
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data of polydisperse suspensions is troublesome because of interferences due to large or high-
refractive-index particles165. TEM measurements are time-consuming because a large number of 
particles need to be analyzed and results are uncertain due to possible artifacts during sample 
preparation. 
Accordingly, there is still the need for a method to determine the environment-dependent size of 
AgNPs in a reliable and easy to access way. Ideally, this method should satisfy three main 
requirements: (i) ability to analyze AgNPs of different size/coating; (ii) minimal sample processing 
before analysis; (iii) employment of facile and affordable equipment. 
In addition to DLS166,167 and TEM159, other techniques have been explored, such as Field Flow 
Fractionation168,169, sedimentation/centrifugation170and UV–visible (UV-vis) spectroscopy171. In 
particular, the UV-vis spectroscopy exploits the surface plasmon resonance (SPR) feature of 
metallic nanoparticles172. Although this is a simple and valuable technique, interactions of 
nanoparticles with ions and biomolecules greatly complicate interpretation of the experimental 
data.  
In this paper, a practical approach and comprehensive guidelines to assess the stability of AgNPs 
in both in vitro and in vivo conditions are presented. In this regard, AgNPs of three different 
nominal sizes (10, 40 and 100 nm), coated with either citrate (CT) or polyvinylpyrrolidone (PVP), 
have been studied in two relevant biological media, namely 10% Fetal Bovine Serum (FBS), which 
resembles the protein composition of a typical cell medium, and mouse plasma, mimicking the in 
vivo conditions.  
Three different techniques, namely UV-vis spectroscopy, DLS and TEM were applied to test their 
suitability in detecting such a wide range of AgNPs conditions.  
The presented study is expected to provide useful insights and practical guidelines to assess the 
AgNPs stability in the tested experimental conditions, therefore contributing to more reliable in 
vitro and in vivo nanotoxicity results. All of this could be of relevance to assess the ability of AgNPs 
to pass biological barriers as well as to reduce their potential risks for humans and environment. 
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Materials and methods 
 
 
Chemicals. Silver Nanoparticles (AgNPs) of 10, 40 and 100 nm in size, coated with either citrate 
(CT) or polyvinylpyrrolidone (PVP), were purchased from NanoComposix (San Diego, USA) and 
used as received. In the text, citrate coated AgNPs of 10, 40 and 100 nm were named 10CT, 40CT 
and 100CT, respectively; the PVP coated AgNPs of 10, 40 and 100 nm were named 10PVP, 40PVP 
and 100PVP. All the suspensions were provided at the concentration of 1.0 mg/mL. Fetal Bovine 
Serum (FBS), poly-L-lysine and sodium citrate were purchased from Sigma Aldrich. Grids for 
electron microscopy characterization were obtained from Pelco. The Mouse Plasma (MP) was 
kindly provided by Mouse and Animal Pathology Lab, Filarete Foundation. Bidistilled water 
(MilliQ, Millipore) was employed in all the experiments. 
Quality control on commercially available AgNPs. The CT- and PVP-coated AgNPs were diluted 
with 2.0 mM sodium citrate buffer and MilliQ water, respectively, and carefully resuspended by 
vigorous shaking. If necessary, samples were sonicated (Elmasonic S 30 H) for up to 30 seconds, in 
accordance with the manufacturer’s instructions. Before use, the AgNPs were characterized by 
DLS, TEM and UV-vis spectroscopy, in order to check the agreement of AgNPs’ size with the 
manufacturer's stated description. Details on the characterization procedure are reported in the 
Supplementary Data. 
Experiments with biological media. Experiments were run in two different biological media 
mimicking the in vitro and in vivo conditions: (i) a typical cell culture medium (fetal bovine serum, 
FBS, 10% v/v) and (ii) mouse plasma (MP, 100% v/v). Indeed, 10% FBS was a widely used 
concentration of FBS in cell culture media, whereas mice were the selected models for further in 
vivo toxicity assessment173. 
Experiments with FBS. The AgNPs were suspended in 1.0 mL of 10% FBS at the concentration of 
50.0 µg/mL and incubated at 37°C. At fixed time points (5 min, 24 h) samples were characterized 
by DLS and UV-vis spectroscopy. To check the effect of FBS concentration on the protein corona 
formation, the same experiments were run in 100% FBS. 
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Experiments with MP. The experiments were run in the same way as with FBS, with the exception 
of the overall volume. Indeed, each AgNPs sample was prepared using 50 µL of MP. The AgNPs 
were suspended in 100% MP at the concentration of 50.0 µg/mL and characterized by DLS and 
UV-vis spectroscopy at determined time points. To assess the effect of the MP concentration, 
experiments were also run using 10% MP. 
Dynamic Light Scattering (DLS). The hydrodynamic diameter of AgNPs in solution was measured 
by DLS technique. Measurements were performed with a Malvern Ζetasizer ZS90 instrument 
operating with a light source wavelength of 633 nm and a fixed scattering angle of 90°. In the 
experiments with FBS and MP, samples were centrifuged (10,000 g, 10 min) at room temperature 
(RT), to pellet the AgNPs-protein complexes and remove excess proteins. The obtained pellet was 
washed three times by resuspending in MilliQ water and changes in mean hydrodynamic 
diameter were measured by DLS. All the measurements were run at RT for at least three times. 
Transmission Electron Microscopy (TEM). The protein corona morphology was studied byTEM (FEI 
Tecnai 200kV). To this aim, Formvar-coated copper grids were previously treated with 0.01% 
(w/v) poly-L-lysine for 10 min and washed with water. Then the AgNPs-protein corona complexes 
were fixed with 2.53% (w/v) glutaraldehyde for 1 h and deposited on poly-L-lysine-coated grids. 
After 15 min, the exceeding samples were removed by washing with water and the grids were left 
under vacuum overnight.  
UV-vis Spectroscopy. The UV-vis spectra were acquired in the 300-800 nm range using a Cary 100 
Spectrophotometer (Agilent). In the experiments with FBS and MP, samples were detected 
without further purification. Since the operating volume in MP experiments was very small, UV-vis 
spectra were acquired using an ultra-low volume cuvette with a 4 mm path length and a 1x2 mm 
window. The absence of aggregates was evaluated by considering absorbance in the wavelength 
range of 600-800 nm. All the measurements were run at RT for at least three times. 
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Results 
 
In order to achieve standardized results, commercially available AgNPs were used in all the 
experiments. Since poorly characterized samples can led to confusing or even mis-interpreted 
results, thorough characterization of AgNPs was performed before any experiment. The results 
obtained by UV-vis spectroscopy, DLS and TEM indicated narrow size distribution and absence of 
any aggregates in the AgNPs suspensions (seeSupplementary data page144). 
To realistically mimic in vitro and in vivo conditions, the stability of AgNPs was tested in fetal 
bovine serum (10% FBS) and mouse plasma (100% MP), being 10% FBS one of the most commonly 
used concentration of FBS in cell culture media and mice the selected models for in vivo toxicity 
assessment173. 
Experiments with FBS. First, the AgNPs stability was detected by DLS, which represents the most 
widely used method to measure the hydrodynamic diameter of nanoparticles in suspension166. 
Although DLS allows for fast and reliable size measurements, exceeding proteins heavily affected 
the analysis. Accordingly, the nanoparticle-protein complexes (Fig. 47 panel A) have to be 
separated from unbound proteins, usually by centrifugation. The purification process consisting of 
three-cycles of centrifugation was successful for 100 nm and partly for 40 nm-sized AgNPs. 
However, the 10 nm AgNPs did not sediment by centrifugation and their DLS results are not 
reported. Due to partial sedimentation, the DLS data of 40 nm-sized AgNPs require careful 
examination (see Supplementary data page144). 
Instead, the DLS results of 100 nm-sized AgNPs, coated with either citrate (100CT) or PVP 
(100PVP) provided several insights in understanding the protein corona formation (Fig. 47). 
Indeed, the hydrodynamic diameter of 100CT (98.5 nm) was found to be higher in 100% FBS 
(191.0 nm) than in 10% FBS (131.0 nm), whereas no differences were visible after incubating 
100PVP (131.0 nm) with either 10% FBS or 100% FBS (205.0 and 208.0 nm, respectively). The 
behavior of 100PVP could be explained by considering the stealthiness of PVP, which prevented 
increase in protein adsorption while increasing the protein content of the suspending medium. 
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Fig. 47. General scheme of AgNPs-protein complexes formation. (A) Size distributions of 100 CT 
(B) and 100 PVP (C) before (solid) and after 24h incubation with 10% FBS (dash) and 100% FBS 
(dot). 
 
To further investigate the nanoparticle-protein interactions, surface charge (ζ-potential) 
measurements were performed. This parameter is important in determining the biological impact 
of the nanoparticle–protein corona complexes because surface charge strongly influences 
interactions with cells and toxicity174. Similarly to DLS analysis, samples were processed by three 
centrifugation cycles to remove excess proteins, which was feasible only for 100 nm and partly 40 
nm-sized AgNPs. Due to limitations in the purification process, the 10 nm-sized AgNPs did not 
provide any affordable result. 
To assess the effect of AgNPs coating on the surface charge, ζ-potential measurements were 
performed on 100CT and 100PVP before and after incubation with 10% FBS and 100% FBS, as 
shown in Fig. 48. 
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Fig. 48. ζ-potential values of 100 nm-sized AgNPs before (ctr) and after 24h incubation with 10% 
FBS (F10) and 100% FBS (F100). 
 
Before incubation, the tested AgNPs were negatively charged. This was expected because sodium 
citrate (CT) and polyvinylpyrrolidone (PVP) as stabilizing agents yield particles with a negative 
surface charge at physiological pH175. After 24 h incubation with either 10% FBS or 100% FBS, the ζ 
potential of both 100CT and 100PVP underwent a decrease in its absolute value (became less 
negative). Although proteins adsorbed onto the AgNPs surface reduced the electrostatic 
repulsions, they were found to stabilize AgNPs and prevent their aggregation176. These data 
suggested that both the most abundant and the most affine proteins were neutral or positively 
charged at physiological pH. 
In order to assess the morphology and size of AgNPs upon incubation with either 10%FBS or 
100%FBS, TEM analyses were performed. The protein corona was clearly visible in 40CT and 
100CT, since a thin layer all over these samples was detected (Fig. 49 panel d and panel f). The 
absence of any artifacts was determined by treating AgNPs controls in the same way (i.e. 
incubation with 2.53% glutaraldehyde), as shown in Fig. 49 panelc and panel e. Notably, the 
protein corona was not observed in 10CT. In particular, besides single NPs, the 10CT showed 
aggregates of several hundreds of nm (Fig. 49 panel b) that could be due to particle aggregation 
during sample drying. 
135 
 
 
 
Fig. 49. TEM images of 10 nm (a, b), 40 nm (c, d) and 100 nm sized (e, f) AgNPs coated with 
citrate. The AgNPs were incubated with 10% FBS for 24 h, then the protein corona was fixed with 
2.53% glutaraldehyde (b, d, f). Control AgNPs were also prepared using the same sample 
processing (a, c, e). Scale bars are 50 nm. 
 
Dealing with the PVP-coated AgNPs, the protein corona was clearly visible in 40PVP and 100PVP, 
whereas aggregates of several hundreds of nm were observed in the 10PVP (Fig. 50).  
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Fig. 50. TEM images of 10 nm (a b), 40 nm (c, d) and 100 nm sized (e, f) AgNPs coated with PVP. 
The AgNPs were incubated with 10% FBS for 24 h, then the protein corona was fixed with 2.53% 
glutaraldehyde (b, d, f). Control AgNPs were also prepared using the same sample processing (a, c, 
e). Scale bars are 50 nm. 
 
 
 
 
Finally, the AgNPs stability in FBS was detected by UV-vis spectroscopy. This is a key technique for 
optical characterization of AgNPs, since they exhibit a characteristic absorbance maximum in the 
visible range, i.e. the surface plasmon resonance (SPR) peak, describing the collective response of 
conduction electrons in a metal under electromagnetic excitation. Optical properties of AgNPs are 
closely related to their size, shape and surface alterations and, furthermore, the SPR is sensitive to 
the surroundings of the NPs at the molecular level. Thus, inspection of the SPR feature would 
137 
 
allow detecting the presence of aggregates and investigatingchanges in the close environment of 
the NPs (such as the protein corona). 
To assess the effect of FBS concentration on protein corona formation, the UV-vis spectra (Fig. 51) 
were acquired by suspending the AgNPs in 10% FBS and 100% FBS. The main optical parameters 
are summarized in Table 20. 
 
 
 
 λmax Hmax Red shift 
ctr F10 F100 ctr F10 F100 F10 F100 
10CT 394 406 403 2.90 2.48 1.25 12 9 
40CT 410 418 417 3.27 2.96 2.42 8 7 
100CT 482 493 489 0.99 1.03 0.98 11 7 
10PVP 397 400 401 1.11 1.14 0.65 3 4 
40PVP 409 415 414 2.7 2.68 2.13 6 5 
100PVP 492 497 493.5 0.83 0.76 0.70 5 1.5 
Table 20. Main optical parameters of AgNPs suspensions in 10%FBS (F10) and 100% FBS (F100). 
Control samples (ctr) were prepared using 2.0 mM sodium citrate buffer and MilliQ water for CT- 
and PVP-coated AgNPs, respectively. λmax: maximum wavelength; Hmax: maximum absorbance. 
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Fig. 51. Absorption peaks of control AgNPs (solid), AgNPs after 24 h incubation with 10% FBS 
(dash), AgNPs after 24h incubation with 100% FBS (dot). 10CT, 40CT and 100CT are AgNPs of 
three different sizes (10, 40, and 100 nm respectively), coated with citrate (CT) as capping agent. 
10PVP, 40PVP and 100PVP are 10 nm, 40 nm and 100 nm AgNPs coated with polyvinylpyrrolidone 
(PVP). Slight evidences of aggregation were found only in the 40CT sample incubated with 10% 
FBS. 
 
 
 
After incubation with either 10% FBS or 100% FBS, the spectral position of the maximum 
wavelength (λmax) of all the tested AgNPs showed a shift towards increasing wavelength values, 
meaning an energy red shift. In the 100 nm-sized AgNPs, a two-fold peaked wide band was 
observed, due to the convolution of the broadened plasmonic band with a band centered on 500 
nm. Therefore, the λmax of the plasmonic band of 100CT and 100PVP is not reported in Table 20 
because the SPR peak feature is lost in these samples.  
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The SPR peak was found to red-shift much more in the CT-coated AgNPs as compared to the PVP-
coated ones. Moreover, the smaller the AgNPs size, the higher was the SPR red-shift, as expected 
due to the enhanced surface-to-volume ratio. 
Further, with the exception of 100 nm-sized AgNPs, a remarkable decrease of the maximum 
absorbance was observed while increasing the concentration of the biological medium (10% FBS 
and 100% FBS). For the CT-coated AgNPs, it was found that the lower the size, the more evident 
was the decrease of Hmax. In particular, the concentration of FBS seemed not to affect the overall 
optical properties of 100CT, since both the height and shape of the absorbance peaks after 
incubation in 10% and 100% FBS medium were pretty similar to the control. However, after 
incubation with either 10% FBS or 100% FBS, the 10CT and 40CT underwent a relevant decrease in 
the maximum absorbance by one third and two-thirds, respectively. A similar trend, although less 
pronounced, was found for the PVP-coated AgNPs. 
Notably, the decrease in absorbance value cannot be ascribed to the formation of AgNPs 
aggregates, whose typical peak in the 600-800 nm range was absent in all the tested samples, 
with the exception of 40CT sample incubated with 10% FBS. To the best of our knowledge, the 
observed decrease in absorbance value after interactions with biological media has not been 
reported so far. 
Experiments with MP. Similarly to FBS experiments, AgNPs samples incubated with either 10% 
or100% MP were characterized by DLS and UV-vis spectroscopy to determine their stability. The 
DLS data provided further evidences of both the protein corona formation and the stealthiness of 
PVP-coated AgNPs (see Supplementary data page144). The UV-vis results are shown in Fig. 52. It is 
worthy to note that MP has a characteristic absorption peak at about 412 nm, which was 
particularly evident in the 100% MP sample. Accordingly, the absorption peaks reported in Fig. 52 
were obtained by subtracting the spectrum of either 10% or 100% MP. 
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Fig. 52. Absorption peaks of control AgNPs (solid) and AgNPs after 24 h incubation with 10% MP 
(dash) and 100% MP (dot). 
 
As in the experiments with FBS, the red-shift of the SPR peak (ascribed to changes in the dielectric 
environment) and the reduction of Hmax were more evident in AgNPs samples with size of 10 and 
40 nm (Table 21). In general, these SPR features in the experiments with MP were found to be 
more pronounced than after incubation with FBS, as expected because MP had numerous 
additional components with respect to FBS, including antibodies. 
 
 λmax Hmax Redshift 
 ctr MP10 MP100 ctr MP10 MP100 MP10 MP100 
10CT 392 399 394 1.357 0.622 0.312 7 2 
40CT 410 412 404 1.956 0.805 0.833 2 -6 
100CT 480 484 469 0.241 0.217 0.174 4 -11 
10PVP 390 402 399 1.131 0.915 0.383 12 9 
40PVP 412 414 413 1.051 1.255 0.593 2 1 
100PVP 481 486 474 0.478 0.549 0.508 5 -7 
Table 21. Main optical parameters of AgNPs suspensions in 10% MP (MP10) and 100% MP 
(MP100). Control samples (ctr) were prepared using 2.0 mM sodium citrate buffer and MilliQ 
water for CT- and PVP-coated AgNPs, respectively. 
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Discussion 
 
It is widely accepted that accurate size measurements under the exposure conditions are required 
to well-design in vitro and in vivo studies and correctly predict the toxicological effects of 
AgNPs163,164. In this work, in order to develop an effective approach to analyze AgNPs of different 
size with minimal sample processing, three different techniques have been considered, namely 
DLS, TEM and UV-vis spectroscopy.  
The DLS has been extensively exploited to determine the particle size and surface charge of AgNPs 
suspended in biological media164. Although DLS measurements are fast and reliable, this 
technique suffers from several limitations. First, it is necessary to separate by centrifugation the 
nanoparticle-protein complexes from exceeding proteins, to achieve accurate analysis and avoid 
sample artifacts. Such a purification, besides the possibility to alter the nanoparticle-protein 
complexes, is critical for small (i.e. 10 nm-sized) AgNPs. Moreover, since serum proteins 
contribute to the scattered light and interfere with signals from AgNPs, the DLS characterization 
of particles in biological media is very challenging165. 
The TEM analysis provided valuable images on the protein corona and nanoparticle distribution. 
However, complex sample preparation can profoundly change the nanoparticle-protein 
complexes and sample artifacts can be formed during sample drying. Therefore, although TEM 
analysis represents a useful inspection tool to gain general morphological information on AgNPs, 
its employment to routinely assess the AgNPs stability is limited165,177.  
Differently, the UV-vis spectroscopyallowed for fast and reliable results with minimal sample 
processing. Since exceeding proteins did not affect the overall optical properties of AgNPs, any 
purification step was required before sample analysis. Accordingly, the UV-vis spectroscopy was 
found to be effective in analyzing the 10 nm-sizedAgNPs, which were difficult to be detected by 
either DLS or TEM. Because of its wide range of applications, the UV-vis spectrophotometer is a 
commonly available tool in biological laboratories, which are usually not equipped with particle 
analysis instruments. Therefore, in situ analyses to assess the AgNPs stability before either in vitro 
or in vivo experiments are feasible. 
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However, interactions of AgNPs with ions and biomolecules in the tested medium may greatly 
complicate the understanding of the UV-vis data, therefore comprehensive guidelines to assess 
the AgNPs stability are demanding. In this work, main criteria for interpreting the UV-vis spectra 
are provided (Table 22). 
 
 λmax Hmax Notes 
Protein corona formation ↑ ↓ The lower the AgNPs size, the more 
accentuated are these changes 
Aggregation - ↓ Absorbance in the 600-800 nm range  
Multiple Abs peaks  
Agglomeration - - No substantial changes in optical 
properties  
 
Table 22.Summary of optical changes observed after protein corona formation, agglomeration 
and aggregation of AgNPs. 
 
The simultaneous increase of the λmax value (namely a red shift) and the reduction of the Hmax 
value are associated to the protein corona formation, thus indicating that nanoparticles are well 
suspended in the tested medium. Notably, the smaller the AgNPs size, the more evident are these 
changes.  
The appearance of multiple absorption peaks, especially in the 600-800 nm range indicate the 
formation of aggregates in terms of fused or strongly bonded AgNPs. Since aggregates do not 
exhibit the SPR absorption peak, under these conditions the Hmax value is reduced. Both the 
appearance of additional absorption peaks and the decrease of Hmax value indicate that 
nanoparticles in the tested media are irreversibly modified. Therefore, any affordable biological 
experiment can be run under these conditions. 
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Finally, the absence of substantial changes in optical properties suggests that AgNPs in the 
medium formed agglomerates, namely weakly bonded particles. An additional evidence of 
agglomeration is provided by the appearance of larger peaks in the DLS analysis. Hence, vigorous 
shaking is sufficient to enable further processing and experiments.  
In summary, here we deeply discuss guidelines for assessing the AgNPs fate under the exposure 
conditions in in vivo and in vitro experiments. AgNPs of three different size (10, 40 and 100 nm), 
coated with either citrate (CT) or polyvinylpyrrolidone (PVP) were tested in two different 
biological media (FBS and MP). Practical drawbacks of Dynamic Light Scattering (DLS) and 
Transmission Electron Microscopy (TEM) in detecting AgNPs were considered and discussed. 
Instead, the UV-vis spectroscopy was found to be the most versatile technique to predict the 
behavior of the wide range of AgNPs conditions. The UV-vis results suggested that the AgNPs’ 
stability was highly dependent on both the size and coating of AgNPs. Indeed, changes were more 
evident in CT- than in PVP-coated AgNPs, in accordance with the current knowledge about PVP, 
which is able to induce stealth behavior and to extend the persistence of nanoparticles inside the 
body. Further, the lower the size of AgNPs, the more pronounced were the optical changes due to 
the protein corona formation and the influence of the suspending biological medium. Finally, the 
increase in nanoparticle hydrodynamic diameter was much higher in the MP than in 10% FBS, as 
expected because of the higher concentration of proteins in MP.  
Overall, the proposed approach based on UV-vis spectroscopy is expected to provide biological 
researchers with useful insights to easily assess the stability of AgNPsin in vitro/in vivo 
experiments, thus contributing to more reliable nanotoxicity results.  
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Supplementary data 
 
Supplementary methods 
 
Quality control of silver nanoparticles (AgNPs). 
 
In order to prevent contamination, measurements were run using disposable plastic cuvettes. The 
AgNPs were tested immediately after their delivery. 
Dynamic Light Scattering (DLS). The actual size of AgNPs in dispersion was measured by DLS. All 
the nanoparticles were diluted 1:100 with the exception of 10 nm-sized AgNPs. Indeed, due to 
their small size, the 10 nm AgNPs presented increased absorption and lower scattering intensity 
compared to 40 nm and 100 nm AgNPs. Accordingly, the 10 nm AgNPs were diluted 1:50. All 
measurements were run at room temperature for at least three times. 
UV-visible (UV-vis) Spectrophotometry. The UV-Vis spectra were acquired in the 300-800 nm 
range using a Cary 100 (Agilent) spectrophotometer. All the nanoparticles were diluted 1:100 with 
the exception of 10 nm AgNPs, which were diluted 1:200 because of their increased UV-Vis 
absorbance with respect to larger nanoparticles. All measurements were run at room 
temperature for at least three times. 
Transmission Electron Microscopy (TEM). Formvar coated copper TEM grids (cod. PE1GC300, 
Pelco) were pre-treated with 20 µl of poly-L-lysine 0.01% (w/v) (Sigma Aldrich) for 15 minutes. 
After washing twice with MilliQ water, 3 µL of AgNPs suspensions were deposited onto the grid 
for 5 minutes and then rinsed with 3 µL of 2-propanol (Sigma Aldrich). According to the 
manufacturer’s advice, 100 and 40 nm AgNPs were used at the concentration of 1.0 mg/mL, while 
10 nm AgNPs were diluted up to 0.1 mg/mL before use. The grids were allowed to dry overnight 
at room temperature in a covered crystallizing dish. TEM (FEI Tecnai G2, Eindhoven) images were 
analyzed with the Image J software to obtain the nanoparticles dimensional distribution. In 
particular, small objects due to background and overlapping nanoparticles were omitted by using 
proper cut-off filters and Feret diameter (intended as the larger diameter of the NP projection) 
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was used to evaluate the size of the particles. For each sample, a minimum of about 250 
nanoparticles was considered. 
 
 
 
 
 
TEM measurements 
 
 
Fig. 53. TEM images of 10 nm, 40 nm and 100 nm-sized AgNPs coated with citrate(CT) and 
polyvinylpyrrolidone (PVP) for quality control. Scale bars are: 1µm for 100 nm-sized AgNPs; 500 
nm for 40 nm-sized AgNPs; 100 nm for 10 nm-sized AgNPs. 
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Particle size analysis 
 
Fig. 54. Feret diameter distributions of 10, 40, 100 nm-sized AgNPs coated with CT or PVP. 
 
Table 23. 
 DLS UV-vis 
 z-average pdI Hmax λmax 
10CT na na 145.5 392 
40CT 38.79 0.153 174.8 409 
100CT 88.96 0.184 49.3 484 
10PVP na na 175.8 391 
40PVP 50.60 0.236 135.5 411 
100PVP 104.4 0.137 46 490 
 
Table 23. DLS and UV-vis results after quality control. DLS data for 10 nm-sized AgNPs were not 
available (na). The Hmaxvalues were calculated considering the AgNPs dilutions. 
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The effect of mouse plasma (MP) concentration on 100 and 40nm AgNPs samples: DLS 
results. 
 
Except the 40PVP sample, the higher the MP content in the suspending medium, the higher was 
the increase in the hydrodynamic diameter, as shown in Fig. 55. 
Overall, the increase in diameter of CT-coated AgNPs was found to be higher than PVP-coated 
ones, further confirming that AgNPs after PVP coating were stealth. 
 
 
 
Fig. 55. Size distributions of 40 and 100 nm-sized AgNPs, coated with either CT or PVP after 24h 
incubation with 10% MP (dash) and 100% MP (dot). The concentration of AgNPs was 50.0 µg/mL. 
Controls are reported as solid line. 
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2. Tissue distribution and acute toxicity of silver after single intravenous 
administration in mice: nano-specific and size-dependent effects 
 
Physicochemical characterization of silver nanoparticles 
 
Commercial AgNPs with a nominal size of 10, 40 and 100 nm were tested in this study. Citrate 
(CT)- and polyvinylpyrrolidone (PVP)-coated AgNPs were investigated to probe the effect of 
surface stabilizing agents. Details provided by the manufacturer on the physic-chemical properties 
of the studied AgNPs are reported in Table 24 page 153. The particles were thoroughly 
characterized before the investigation of their toxicological effects in vivo and their accordance to 
manufacturer’s specifications assessed. A rigorous characterization of the test dispersions is 
prerequisite to produce data that can help provide scientific answers to regulatory issues, which 
are impelling for a widely used nanomaterial type such as AgNPs. 
Three different techniques were employed, namely Dynamic Light Scattering (DLS), UV-visible 
(UV-Vis) spectroscopy, and Transmission Electron Microscopy (TEM). First, the hydrodynamic 
diameter of the particles and their possible aggregation when suspended in the testing medium 
were evaluated by DLS. The results are summarized Table 25 page 154. Monomodal distributions 
were observed for 40 nm and 100 nm AgNPs, coated with both CT and PVP. The 10 nm AgNP-CT 
and 10 nm AgNP-PVP suspensions showed multimodal distributions. In particular, the peaks at 
18.1 and 19.6 nm were indicative of isolated nanoparticles in 10 nm AgNP-CT and 10 nm AgNP-
PVP, respectively, while larger peaks in both samples suggested the possible presence of 
aggregates with variable dimensions. However, these large peaks were still detected by DLS even 
after filtration (0.22 µm pore size), thus indicating their dynamic nature. 
To further investigate the intrinsic features of the putative aggregates detected in 10 nm AgNPs, 
UV-vis spectroscopy measurements were performed. AgNPs exhibit a characteristic absorbance 
maximum in the visible range due to the surface plasmon resonance (SPR) effect172. Notably, 
optical properties of AgNPs are closely related to their morphology, therefore UV-vis spectroscopy 
is able to detect any change in size/shape as well as the presence of aggregates. The UV-vis results 
are shown in Table 25 page 154. The correspondence between the optical properties given by the 
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manufacturer and those measured in our laboratory appeared satisfactory; in particular, no 
decrease in the maximum absorbance value (Hmax) was observed, indicating absence of 
aggregates. Then, full absorbance spectra of all samples were considered (Figure 56). The optical 
density in the 600-800 nm range, which is typical for aggregate absorption, was not detected in 10 
nm AgNP-CT and 10 nm AgNP-PVP, further demonstrating that the presence of stable aggregates 
in these samples could be excluded178. 
 
 
Figure 56. Particle characterization by UV-vis spectroscopy: full absorbance spectra of the tested 
silver nanoparticles. The optical density in the 600-800 nm range, which is typical for aggregate 
absorption, was not detected in any of tested AgNPs, indicating the absence of stable aggregates 
in these samples. 
 
Eventually, TEM analysis was performed to assess the shape and primary size distribution of 
tested AgNPs. All the tested AgNPs were spherical in shape (Figure 57), and their Feret diameter 
distributions were in good accordance with data reported by the manufacturer (p > 0.05 in all 
cases) (Table 25 page 154). 
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Figure 57. TEM of silver nanoparticles. Representative transmission electron micrographs of 
tested 10, 40, 100 nm AgNPs,CT- and PVP-coated. All purchased particles were spherical in shape, 
and no stable aggregates were visible (scale bar is 100 nm). 
 
According to these analyses, both the 10 nm AgNP-CT and the 10 nm AgNP-PVP gave questionable 
DLS results, since peaks by far larger than 10 nm were detected. Similar findings were recently 
reported for AgNPs with size lower than 20 nm and 15 nm163. Here, the absorbance spectra clearly 
confirmed the absence of any stable aggregate, since neither the Hmax decrease nor the 
absorbance in the 600-800 nm range were visible. TEM analysis further confirmed the absence of 
aggregates. Therefore, the large peaks detected in the DLS analyses of 10 nm AgNPs were 
ascribed to dynamic aggregates, which are unstable and do not represent a problem for in vivo 
experiments. In conclusion, the characterization by DLS, UV-vis spectroscopy, and TEM of 
purchased AgNPs suspensions confirmed the data certified by the manufacturer and their 
suitability for in vivo administration. 
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Methods 
 
Characterization of silver nanoparticles. Suspensions of BioPureTM Silver Nanoparticles (AgNPs) of 
10, 40 and 100 nm in size, coated with either citrate (CT) or polyvinylpyrrolidone (PVP), were 
purchased from NanoComposix (San Diego, USA). All the suspensions were supplied at a 
concentration of about 1.0 mg/mL. BioPureTM AgNPs were chosen because they were guaranteed 
to be sterile and with an endotoxin level lower or equal to 2.5 EU/mL. Before use, the CT and PVP-
coated AgNPs were diluted with 2.0 mM sodium citrate (cod. W302600, Sigma-Aldrich) buffer and 
MilliQ water (Millipore), respectively. When necessary, samples were sonicated (Elmasonic S 30 
H) for up to 30 seconds, in accordance with the manufacturer’s instructions. In order to prevent 
contamination, measurements were run using disposable plastic cuvettes. The AgNPs were tested 
immediately after their delivery and in vivo experiments were run in the following week. In the 
meanwhile, the AgNPs were stored at +4°C, according to manufacturer’s instructions.  
Dynamic Light Scattering (DLS). The actual size of AgNPs in dispersion was measured by DLS. 
Measurements were performed with a Malvern Zetasizer Nano ZS90 instrument operating with a 
light source wavelength of 633 nm and a fixed scattering angle of 90°. All the nanoparticles were 
diluted 1:100 with the exception of 10 nm-sized AgNPs. Indeed, due to their small size, the 10 nm 
AgNPs presented increased absorption and lower scattering intensity compared to 40 nm and 100 
nm AgNPs. Accordingly, the 10 nm AgNPs were diluted 1:50. All measurements were run at room 
temperature for at least three times.  
UV-Visible (UV-Vis) Spectrophotometry. The UV-Vis spectra were acquired in the 300-800 nm 
range using a DU730 Beckman Coulter Spectrophotometer. All the nanoparticles were diluted 
1:100 with the exception of 10 nm AgNPs, which were diluted 1:200 because of their increased 
UV-Vis absorbance with respect to larger nanoparticles. All measurements were run at room 
temperature for at least three times. 
Transmission Electron Microscopy (TEM). Formvar coated copper TEM grids (cod. PE1GC300, 
Pelco) were pre-treated with 20 µL of poly-L-lysine 0.01% (w/v) (Sigma Aldrich) for 15 minutes. 
After washing twice with MilliQ water, 3 µL of AgNPs suspensions were deposited onto the grid 
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for 5 minutes and then rinsed with 3 µL of 2-propanol (Sigma Aldrich). According to the 
manufacturer’s advice, 100 and 40 nm AgNPs were used at the concentration of 1.0 mg/mL, while 
10 nm AgNPs were diluted up to 0.1 mg/mL before use. The grids were allowed to dry overnight 
at room temperature in a covered crystallizing dish. TEM (FEI Tecnai G2, Eindhoven) images were 
analyzed with the ImageJ software (http://imagej.nih.gov/ij/) to obtain the nanoparticles 
dimensional distribution. In particular, small objects due to background and overlapping 
nanoparticles were omitted by using proper cut-off filters and Feret diameter (intended as the 
larger diameter of the NP projection) was used to evaluate the size of the particles. For each 
sample, a minimum of about 250 nanoparticles was considered. 
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Table 24. Main physicochemical properties of tested AgNPs provided by the manufacturer and 
reported in the datasheet. 
 
 
CT = sodium citrate; PVP = polyvinylpyrrolidone. na = not available (not reported in the 
datasheet). 
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Table 25. Physicochemical characterization of tested AgNPs. The main findings in AgNPs 
characterization are reported for each tested sample. For DLS analyses, the mean size of AgNPs is 
expressed in terms of hydrodynamic diameter, however this parameter is fully informative only 
for samples with monomodal distributions. Accordingly, the maximum intensity peaks were also 
reported to describe more comprehensively samples having multimodal distributions (i.e. 10 nm 
AgNP-CT and 10 nm AgNP-PVP). The pdI provides a measure of particles uniformity. For UV-Vis 
analyses, the maximum wavelength (λmax, i.e. the wavelength corresponding to the highest 
absorbance of AgNPs) and the maximum absorbance value (Hmax) are reported. The λmax and Hmax 
values were expressed in nanometer (nm) and arbitrary units (a.u.), respectively. Finally, AgNPs 
size distributions expressed as Feret diameter (mean ± SD, nm) and variation coefficient (%) were 
obtained from TEM analysis. 
BiopureTM Silver 
nanoparticle 
DLS UV-Vis TEM 
Mean 
hydrodynamic 
diameter 
Max 
intensity 
peaks 
pdI λmax Hmax Diameter 
Variation 
coefficient 
 
(nm) (nm) 
 
(nm) (a.u.) 
(mean±SD, 
nm) 
(%) 
10 nm AgNP-CT np 
18.1- 
4046 
0.258 392 
163.
5 
8.4±1.5 25.4 
10 nm AgNP-PVP np 
19.6– 
111– 
4292 
0.343 389 
163.
6 
10.8±2.6 24.0 
40 nm AgNP-CT 40.1 49.8 0.213 412 
152.
6 
39.3±4.8 12.3 
40 nm AgNP-PVP 51.8 67.6 0.251 410 
145.
7 
40.3±5.6 13.9 
100 nm AgNP-CT 87.6 102.9 0.148 490 45.1 107.7±10.5 9.8 
100 nm AgNP-PVP 104.1 119.4 0.124 491 46.8 105.5±10.9 10.4 
 
np = not provided for samples with multimodal distributions 
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3. Fill the gap in the nanomaterials legislation: determination of the partition 
coefficient of silver nanoparticles 
 
Abstract 
 
Partition coefficient (P) is a key parameter in safety assessment, being predictive for membrane 
permeability, bioaccumulation and biomagnification. However, to date legislation of 
nanomaterials has poorly considered this parameter to assess their safety and no protocols using 
P are reported. In general few studies are present in literature to determine P value of 
nanomaterials. Since silver nanoparticles (AgNPs) represent one of the most used nanomaterials 
in commercial products, a novel method based on shake flask principle is here presented to assess 
their P value. AgNPs having 100 nm in size and citrate (CT-AgNPs) or PolyVinylPyrrolidone (PVP-
AgNPs) as surface coating were selected and the influence of different parameters (shaking time, 
pH and proteins interaction) on P evaluation was investigated.  
First, after three hours shaking the partition equilibrium was reached for both CT- and PVP-AgNPs; 
however the water-octanol distribution was different, being the PVP-AgNPs completely moved in 
the organic phase, while the CT-AgNPs still remained in the aqueous one. Nevertheless this 
distribution was dependent on pH and ionic strength of the aqueous phase: the higher the pH the 
more AgNPs preferred the aqueous phase, both for CT and PVP coating. Finally, the formation on 
purpose of a protein corona around each single AgNPs minimized differences in phase distribution 
since both CT- and PVP-AgNPs were stabilized in the aqueous phase at each pH tested.  
 
Introduction 
 
The partition coefficient (P) is defined as the ratio of the equilibrium concentrations of a dissolved 
substance in a two-phase system, composed by immiscible solvents, commonly water and n-
octanol179. Undoubtedly, P is a measure of hydrophobicity and, since several biological processes 
are driven by this property, P assessment is potentially predictive of materials behavior when 
interacting with biosystems180,181. For instance, P can be considered an indirect measurement of 
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permeability being directly correlated to passive diffusion through biological membrane by the 
Fick’s second Law182. In addition, the accumulation capacity of a substance in lipids is commonly 
assumed to be identical to that in n-octanol183. This means that P can help predicting the 
accumulation of a determined substance in the adipose tissues but also its bioaccumulation factor 
in the food chain184. Moreover, P evaluation is fundamental in ecotoxicology, since hydrophobicity 
may also influence soil sorption180,184.  
As far as chemicals are concerned, P have been thoroughly studied in the nineteenth and 
twentieth century185 and it is nowadays required as mandatory parameter to be reported in 
different legislation and guidelines from both Europe and United States, such as “Registration, 
Evaluation, Authorization, and Restriction of Chemicals” (REACH), “Organization for Economic co-
operation and Development”(OECD), and “Toxic Substances Control Act” (TSCA). In addition, 
relationships between P and organic carbon content, toxicity and bioaccumulation factor have 
been thoroughly studied and nowadays software are available to predict chemicals fate, 
especially in the environment183.  
When nanomaterials (NMs) are taken into account, the importance of P is still on debate. In fact, 
in the OECD “Guidance manual for the testing of manufactured nanomaterials (NMs)” edited in 
2009186, P was considered mandatory as parameter when technical dossiers should be provided. 
In addition, reviews are available187,188 on the importance of P as hydrophobicity index for toxicity 
and fate protocols, also for nano-sized materials. However, very recently the same OECD 
commission189 expressed the opinion that P evaluation is irrelevant, being the test available for P 
assessment not suitable to investigate a distribution mechanism peculiar for NMs. The task is 
challenging and debated. Actually, it is well-known that NMs behave differently with respect to 
their bulk form52 but strict protocols on how to evaluate NMs physical-chemical characteristics are 
not available yet. One of the major hurdle in this area is the lack of standardized methods187 to 
assess NMs properties, including surface area, charge, size, shape, and morphology183. In 
particular, hydrophobicity assessment in NMs is one of the most tricky task because of NMs 
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interference in interfacial phenomena188. In the literature very few data are available on P 
assessment on NMs and the most majority were obtained with not standardized materials187. 
In answer to the call for protocol harmonization in the physical-chemical characteristics of NMs, 
the present work was aimed at exploring the potential of the classical shake-flask method179 to 
evaluate P for NMs. Shake-flask is the preferred method in P evaluation for chemicals due to its 
simplicity and robustness but no evidences are available for its suitability also for NMs. In this 
study, attention was focused on silver nanoparticles (AgNPs). In fact, they represent the most 
widely commercialized NMs in industry thanks to their antiseptic activity and potential for 
adverse effects in humans is very high. However, very few studies are present in the literature 
assessing AgNPs physical-chemical properties, including P. Moreover, these studies often 
employed AgNPs without a complete characterization in term of size and size distribution. To 
overcome these limitations, commercial AgNPs (Biopure, Nanocomposix, San Diego, US) having a 
mean size of 100 nm and with two different coatings, namely citrate (CT) and 
PolyVinylPyrrolidone (PVP), were investigated. Additionally, different parameters were considered 
in the experimental setup, including shaking time, temperature, aqueous medium pH and ionic 
strength. Finally, the interaction of proteins with AgNPs to form a “protein corona” and its impact 
in P assessment were evaluated. Easy-to-manage techniques, such as UV-Visible spectroscopy 
(UV-Vis, Cary 100, Agilent) and Dynamic Light Scattering (DLS, Zetasizer NanoZS, Malvern 
Instruments) were used to determine AgNPs concentration and morphology, respectively. 
 
Materials and methods 
 
Materials 
Silver Nanoparticles (AgNPs) of 100 nm in size, coated with either citrate (CT-AgNPs) or 
polyvinylpyrrolidone (PVP-AgNPs), were purchased from NanoComposix (San Diego, USA) and 
used as received. All the suspensions were provided at the concentration of 1.0 mg/mL. 1-octanol, 
Fetal Bovine Serum (FBS), sodium citrate, sodium chloride, potassium chloride, sodium 
phosphate, potassium phosphate, hydrochloric acid and sodium hydroxide were purchased from 
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Sigma Aldrich. MilliQ water was used in all the experiments. Experiments were run at the 
concentration of 15.0 µg/mL. However, since AgNPs can partially degrade in stock conditions, 
their nominal concentration was always assessed before starting the experiments.  
 
Adapted shake-flask method experiments. To reproduce the shake-flask method, 500 µL of 1-
octanol were added to 500 µL of aqueous AgNPs solution (15.0 µg/mL) in a glass vial. Different 
aqueous phases were considered. In particular, citrate 2 mM was used to set the experimental 
parameters, whereas Phosphate Buffer Saline (PBS) 0.1X was selected to mimic physiological 
conditions. By properly adding concentrated HCl or NaOH, three PBS buffer having different pH 
values were obtained, namely, 3.0 to mimic the gastric compartment, 5.5 for the epidermis and 
8.0 for the large intestine. Samples were let under constant rotation. After the appropriate timing, 
the formed emulsions were left at room temperature (RT) until a complete separation of the two 
immiscible phases was reached. The upper organic phase was removed and the aqueous one was 
analyzed by both Dynamic Light Scattering and UV-Vis spectroscopy.  
Dynamic Light Scattering (DLS). The hydrodynamic diameter of AgNPs in solution was measured 
by DLS technique. Measurements were performed with a Malvern Zetasizer ZS90 instrument 
operating with a light source wavelength of 633 nm and a fixed scattering angle of 90°. All the 
measurements were run at RT for at least three times. 
UV-Vis Spectroscopy. The UV-Vis spectra were acquired in the 300-700 nm range using a Cary 100 
Spectrophotometer (Agilent). All the measurements were run at RT for at least three times. 
AgNPs concentrations before and after the partition experiments were calculated by means of 
calibration curves. AgNPs were diluted in citrate 2mM at the concentrations of: 0.0 - 2.5 – 7.5 – 
12.5 – 17.5 – 22.0 μg/mL. At least five curves were constructed by taking into account the 
maximum wavelength of absorbance, 480 nm for CT-coated and 490 nm for PVP-coated AgNPs, 
respectively. From a linear regression calculation, equations used for AgNPs concentration 
evaluation were: 
Y = 0.054 x (Pearson 0.9998) for CT-coated AgNPs 
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Y = 0.041 x -0.002 (Pearson 0.9987) for PVP-coated AgNPs 
 
Experiments with protein corona. In order to better mimic a biological exposition, the AgNPs were 
suspended in FBS at the concentration of 30.0 µg/mL and incubated at 37°C. After 24 hours, 
samples were purified by centrifugation (10,000g, 10 minutes, RT, thrice). The final pellets were 
resuspended in the appropriate aqueous medium (citrate 2 mM, PBS 0.1X pH 3, PBS 0.1X pH 5.5 
and PBS 0.1X pH 8), and the nominal starting concentration of 15.0 µg/mL was restored. Protein 
corona formation was assessed by the increase in the hydrodynamic diameter by DLS analyses. At 
least three samples were prepared for each experiment. 
Partition coefficient calculation. P was calculated as the logarithm of the ratio between the 
aqueous and the organic phase concentration, the latter one obtained as the difference between 
initial and final concentration in the aqueous phase179.  
 
Conclusions 
 
In this study, shake-flask method was applied to determine P for commercial 100nm AgNPs, with 
two different coatings, citrate and PVP. In a standardized setting, with citrate 2 mM as aqueous 
phase, the water-octanol distribution was found to be dependent on the AgNPs coating. Being the 
AgNP-PVP partitioned preferentially in the organic phase, they resulted potentially more 
hydrophobic and toxic than the AgNP-CT. The partition experiments and the AgNPs stability were 
not affected by temperature but resulted strongly dependent on the aqueous phase pH. In fact, 
CT-AgNPs stability was higher at higher pH, also for the controls. In this context, the potential 
toxicity of AgNP-PVP was found to be higher at pH 3. Finally, protein corona formation was 
investigated. The variability in the AgNPs partitioning and the potential toxicity of both CT- and 
PVP-AgNPs were found to be reduced at all the tested pH. In particular, PVP-AgNPs was more 
hydrophilic than CT-AgNPs. Evidently, the different composition in the protein corona attributed 
new characteristics at the AgNPs surface.  
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